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HER2-postive breast cancer constitutes approximately 25% of breast cancer 
patients and leads to a worse prognosis. Antibody therapy, such as the anti-HER2 
antibody trastuzumab, is used in the clinical setting to treat these cancers. Unfortunately, 
these cancers can resist trastuzumab treatment through ligand-mediated HER2/HER3 
signaling. The first study addresses this issue by engineering a bispecific antibody 
targeting HER2 and HER3. A combination of immunoblots and proliferation assays 
were used to characterize the interaction between HER2, HER3, and the bispecific 
antibody. Another treatment for HER2-expressing cancers is the antibody-drug 
conjugate (ADC), trastuzumab emtansine (T-DM1). ADCs, however, suffer from a small 
therapeutic window due to a low maximum tolerated dose. The second study addresses 
this issue by engineering variants of the anti-HER2 antibody pertuzumab to bind HER2 
tightly at neutral pH and weakly at acidic pH—termed acid-switched—using phage 
display and histidine scanning. Acid-switched antibodies were then used to generate 
ADCs that were characterized in vitro by flow cytometry, mass spectrometry, and 
cytotoxicity assays. Mice bearing tumor xenografts were treated with acid-switched 
ADCs to test their potency in vivo. 
 Ligand-induced HER2/HER3 dimers activate the PI3K/Akt signaling axis and 
individual treatments such as trastuzumab or the small molecule inhibitor lapatinib 
which targets HER2 phosphorylation are unable to prevent this signaling cascade. The 
bispecific antibody was constructed from trastuzumab and an anti-HER3 antibody with 
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the goal of preventing HER2/HER3 dimer signaling. A combination treatment of the 
bispecific antibody and lapatinib significantly inhibited cancer cell proliferation in vitro. 
 Acid-switched ADCs were engineered to bind tightly to HER2 on the target cell 
surface and to dissociate after internalization into acidic endosomes. These acid-
switched antibodies were observed to have at least an ~100-fold reduced binding affinity 
at pH 5.8 relative to pH 7.4. The difference in binding affinity led to enhanced 
accumulation of acid-switched ADCs and greater release of cytotoxic drug in HER2-
expressing cancer cells in comparison to treatments with ADCs derived from the parent 
antibody. Mice implanted with the HER2-expressing cancer cell lines MDA-MB-453 
and JIMT-1 showed tumor regression or slowed growth when treated with acid-switched 
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Ab6tet – Ab6 antibody with Ab6 scFv 
ADCC – Antibody-dependent cellular cytotoxicity 
ADCP – Antibody-dependent cellular phagocytosis 
ADC – Antibody-drug conjugate 
Akt – Protein kinase B 
ALT – Alanine transaminase 
ATCC – American Type Culture Collection 
AUC – Area under the curve 
BsAb – Bispecific antibody 
CDC – Complement-dependent cytotoxicity 
CL – Constant light 
CH – Constant heavy 
CHO – Chinese hamster ovary 
DAR – Drug-antibody-ratio 
DMSO – dimethyl sulfoxide 
EGFR – Human epidermal growth factor receptor 1 
ELISA – Enzyme-linked immunosorbent assay 
ERK – Extracellular signal-regulated kinases 
Fab – fragment antigen binding  
Fc – fragment crystallizable 
FcγR – Fc gamma receptor 
FcRn – neonatal Fc receptor 
Fv – variable fragment 
HER2 – Human epidermal growth factor receptor 2 
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HER3 – Human epidermal growth factor receptor 3 
HPLC – High-performance liquid chromatography 
HIC – Hydrophobic interaction column 
HRG – Heregulin beta 1 
IgG – Immunoglobulin G 
Lap – Lapatinib 
LC-MS/MS – Liquid chromatography with tandem mass spectrometry 
MMAE – Monomethyl auristatin E 
MTS – 3-(4,5-DimethylThiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt 
MTX - Methotrexate 
VH – Variable heavy 
VHH – Single-domain antibody 
VL – Variable light 
PAb6 – Pertuzumab with Ab6 scFv 
PI3K – Phosphatidylinositol 3-kinase 
PBS – Phosphate buffered saline 
PBST – Phosphate buffered saline with Tween-20 
PVDF – Polyvinylidene difluoride 
ScFv – Single-chain variable fragment 
TAb6 – Trastuzumab IgG with Ab6 scFv 
TBS – Tris-buffered saline 
TBST – Tris-buffered saline with Tween-20 
T-DM1 – Trastuzumab emtansine 
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1. INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Antibody therapeutics 
1.1.1 Antibody structure and function 
Antibodies are proteins created during the process of the adaptive immune 
response to specifically target foreign antigens. Overall, there are 5 different classes of 
antibodies (IgG, IgE, IgM, IgD, and IgA) that are distinguished by their constant 
domains. IgGs are further subdivided into four separate subclasses: IgG1, IgG2, IgG3, 
and IgG41. Therapeutic antibodies are typically based on IgG1 because this subclass 
displays potent effector functions and is highly prevalent in the body2.  Examples of 
IgG1-based therapeutic antibodies include the anti-HER2 antibodies trastuzumab3 and 
pertuzumab4, both of which are used in the studies presented in this thesis. 
IgG1 is a Y-shaped molecule that consists of separate polypeptide chains—two 
identical heavy chains (HCs) and two identical light chains (LCs). The HC is an ~50 kDa 
polypeptide chain consisting of a variable domain (VH) and three constant domains 
(CH1, CH2, and CH3), while the LC is an ~25 kDa polypeptide and is composed of a 
variable domain (VL) and a constant domain (CL). Furthermore, the CL domain is 
subdivided into two classes, kappa (κ) and lambda (λ). The hinge region, a flexible 
amino acid stretch, connects the CH1 domain to the CH2 domain. Two disulfide bonds 
located in the hinge region links two HCs together. A third disulfide bond in the hinge 
region connects to the CL, connecting the HC with the LC. The IgG can be further 
divided into two components—the Fab fragments (fragment antigen-binding) and the Fc 
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fragment (fragment crystallizable region). Each of the two Fab fragments is composed of 
the VH, CH1, VL, and CL domains, whereas the Fc fragment consists of the two CH2 
and CH3 domains. Additionally, the combination of a single VH and VL domain is 





Figure 1-1. Illustration of IgG1 antibody structure. The heavy chain (HC) and light chain 
(LC) are shown in purple and yellow, respectively. Domains of both HC and LC are 
indicated. The three red circles on top of the VH and VL domains represent the three 
complementarity-determining regions (CDRs) on each respective gene. Hinge disulfide 
bonds are represented by green lines. 
 
The Fab fragments of the antibody are responsible for binding to antigen. The 
VH and VL domains each have three complementarity-determining regions (CDRs) that 
together, are responsible for binding to a specific antigen. Through V(D)J 
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recombination5, a unique mechanism by which a wide array of Ig gene segments are 
spliced to create a highly diverse antibody repertoire, B cells are able to generate 
antibodies to target a wide range of antigens. The affinity for these antigens can be 
further enhanced through affinity maturation, an iterative process that involves the rapid 
introduction of mutations into the CDRs and the clonal selection of high affinity binders. 
Unlike the variable domains, the constant domains, HC and LC, are relatively well 
conserved. The Fc portion of the antibody has multiple binding sites located on the CH2 
and CH3 domains and is important for many antibody effector functions along with 
antibody homeostasis within the body. Effector functions such as antibody-dependent 
cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), are 
initiated through the binding of the CH2 domain to Fcγ receptors and complement 
proteins, respectively6-8. 
 
1.1.2 Antibodies as therapeutics 
The first major hurdle for the use of antibodies as a therapy was the ability to 
produce large amounts of monoclonal antibodies—antibodies that bind the same epitope. 
This issue was first addressed in 1975 by Köhler and Milstein through hybridoma 
technology9. An antibody-producing B cell is fused with an immortal myeloma cell to 
create a hybrid cell that is not only able to secrete the desired monoclonal antibody, but 
can also be propagated indefinitely. The creation of hybridoma cells was essential in 
providing the machinery necessary for producing large quantities of select homogenous 
antibody. Shortly after the introduction of hybridoma technology, muromonab-CD3 was 
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clinically approved for the treatment of acute allograft rejection in renal transplants10. 
However, the use of muronmonab-CD3 was limited due to the immunogenic response 
that was mounted against the murine antibody10, 11, and to the antibody’s short half-life 
which results from the low affinity of human neonatal Fc receptor (FcRn) to rodent 
antibodies12. Various strategies have been implemented that either produce chimeric or 
humanized antibodies to prevent the host’s immune system from targeting and removing 
the rodent antibodies. Examples of chimeric or humanized therapeutic antibodies are as 
follows: 
1. Rituximab, a clinically approved chimeric antibody against CD20, was
created by grafting murine VH and VL domains onto human IgG1 constant 
domains13.  
2. Alemtuzumab, an anti-CD52 antibody, was the first therapeutic humanized
antibody14. The CDRs of a rodent anti-CD52 antibody was cloned into
human IgG1, replacing the original IgG’s CDRs. Overall, this antibody 
would be a human IgG1 with rodent CDR sequences which is a significant 
reduction in comparison to rituximab in exposed rodent protein sequences, an 
entire Fv in comparison to the CDRs, for the body to generate an immune 
response to15, 16. 
3. Trastuzumab, an antibody clinically approved for the treatment of HER2-
overexpressing breast cancers, was designed by further humanizing a 
chimeric anti-HER2 antibody (mumAb4D5)3. The chimeric anti-HER2 
6 
 
antibody was humanized by gene conversion mutagenesis3 where the rodent 
sequences of the antibody were mutated to resemble human sequences. 
Fully human antibodies against target antigen can also be created. Humira, the first 
clinically approved fully human monoclonal antibody, was discovered by phage display 
against tumor necrosis factor alpha (TNFα) using a process known as chain shuffling17.  
In summary, the use of antibody-based therapies has become prominent for treating 
multiple diseases including cancer. 
 
1.1.3 Mechanism of action of therapeutic antibodies against cancer 
Therapeutic antibodies for cancer treatment target antigens that are usually over-
expressed on the surface of tumor cells, whereas expression levels on normal cells are 
substantially lower. HER2, for instance, can be found on breast cancer cells but has 
limited expression on normal cell types18. Antibodies can be engineered to target 
surface-expressing tumor antigens to treat cancer through multiple mechanisms: 
1. Antibodies can inhibit signaling by binding key epitopes on either ligand or 
receptor and preventing them from binding to one another. MM-12119, for 
instance, binds to domain I of HER3, preventing the HER3 receptor from 
binding its ligand heregulin and undergoing a conformational change to 
interact with other receptors. Pertuzumab, an anti-HER2 antibody, binds to 
the dimerization arm of HER2 (domain II) and prevents ligand-dependent 
signaling in HER2-overexpressing cancers. Trastuzumab, an anti-HER2 
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antibody, binds to domain IV of HER2, preventing ligand-independent 
signaling of HER220. 
2. Cancer cells opsonized by antibodies can activate CDC. Opsonized cells can 
recruit complement proteins, such as the C1 proteins, which recruit 
macrophages and neutrophils to phagocytose cancer cells and cause 
inflammation21. The formation of a membrane attack complexes (MAC) can 
also be activated through CDC, however membrane-bound regulators often 
prevent MAC formation22. Rituximab, for instance, is known to function 
through CDC in treating leukemia21. 
3. Opsonized cancer cells can recruit immune cells such as natural killer (NK) 
cells, macrophages, and monocytes to actively lyse the cell in a process 
known as ADCC23, 24. Bound antibodies interact with FcγRIIIa on the NK 
cell surface and activates the NK cells25. The activated NK cells release 
proteases, perforin, granzymes, and cytotoxic factors to kill the opsonized 
cell. ADCC has been shown to contribute to trastuzumab’s efficacy against 
HER2-positive breast cancer26.  
4. Opsonized cancer cells can also recruit macrophages and other phagocytes to 
fully engulf whole cells and degrade them in a process known as antibody-
dependent cellular phagocytosis (ADCP). Antibody-coated cells are detected 
by Fc gamma receptors on macrophages or phagocytes, where cross-linking 
of the Fc gamma receptors initiates ADCP27.  In vivo studies have shown that 
ADCP is important in the clearance of certain tumors28. 
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5. Trogocytosis, or “nibbling” of cell membrane can occur on opsonized cancer 
cells. Similar to phagocytosis, the macrophages detect and initiate 
trogocytosis of opsonized cells through their Fc gamma receptors29, 30. In 
contrast to phagocytosis where the macrophage engulfs the opsonized cell, in 
trogocytosis the macrophage only removes small portions of the opsonized 
cell, and internalizes it, which can lead to cell death31, 32.  
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1.2 Bispecific antibodies 
1.2.1 Bispecific antibodies as a therapeutic treatment 
Monoclonal antibodies, by design, are only able to bind to a single epitope of an 
antigen. However, cancer cells can overcome antibody therapy by downregulating the 
expression of the target antigen, mutation of the target epitope, or dimerization with 
other surface receptors. Bispecific antibodies (bsAbs) address some of these issues by 
simultaneously targeting multiple epitopes or antigens. While the application of two or 
more separate monoclonal antibodies is possible, the use of a bsAb has certain 
advantages33, 34. Targeting two different antigens enhances specificity for the target 
cell35. Furthermore, targeting two separate receptors on cancer cells can promote anti-
proliferative effects and prevent the development of resistance36. In some cases, bsAbs 
are used to recruit immune cells to the target cell by targeting an antigen on the target 
cell and a receptor on the immune cell37-39.  Moreover, the combination of two separate 
antibodies into a bsAb reduces the cost of development and clinical trials40.  
 
1.2.2 Format of bispecific antibodies 
In contrast to a traditional antibody, bsAbs can come in multiple structural 
formats. bsAbs can be as simple as two separate single-domain antibodies (VHH)41 or 
two separate single-chain variable fragments (scFv; composed of a VH and VL 
domain)42 attached to one another with a short peptide linker. Other small bsAbs include 
two separate Fabs attached to one another43 or a number of combinations of the above 
mentioned fragments. Traditional antibodies can be engineered to become bsAbs 
10 
 
through cloning techniques. While early bsAbs were produced by hybrid hybridomas or 
chemical conjugation of two antibodies44-47, current bsAbs can be generated using 
molecular biology techniques such that additional VHHs, scFvs, or Fabs are cloned as 
part of an antibody and produced from cultures of mammalian cells [e.g. Chinese 
hamster ovary (CHO) cells and human embryonic kidney (HEK293) cells]48. 
Technologies such as knobs-into-holes mutations in the Fc region49, 50, Fab domain swap 
(CrossMAb)51, and electrostatic steering mutations in the Fc region52, 53 allow a single 
antibody to have Fabs that target different antigens or epitopes.  (Figure 1-2) 
11 
Figure 1-2. Possible bispecific antibody (bsAb) formats. Two single-domain antibodies 
(VHH, a) single-chain variable fragments (scFv, b) and Fabs (c) can be combined by a 
linker to form bsAbs. Combinations of (a), (b), and (c) can be combined with a linker to 
create a VHH-scFv bsAb (d), VHH-Fab bsAb (e), or a scFv-Fab bsAb (f). IgGs can also 
be engineered to have an additional VHH or scFv domain to create IgG-VHH (g) and 
IgG-scFv (h) bsAbs, respectively. Introduction of knobs-into-holes mutations (i), 
swapping of domains (CrossMAb, j), or eletrosteering mutations (k) can allow IgG to 
bind two separate antigens. 
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1.2.3 Bispecific antibodies as a therapeutic agent 
As mentioned above, bsAbs differ from monoclonal antibodies in their ability to 
target two separate antigens. bsAbs can be divided into two separate groups based on the 
antigens they target. One type of bsAb is designed to bind disease/cancer antigens as one 
target and immune cell receptors as the other target. Such bsAbs have the ability to 
recruit immune cells to the diseased/cancer cell and enhance immune responses such as 
ADCC. Examples of this design are MDX-H210 (targeting HER2 and CD64)54, 
catumaxomab (anti-EpCAM and CD3)55, and blinatumomab (anti-CD3 and anti-
CD19)42. The other type of bsAbs target two antigens, or two different epitopes on the 
same antigen (e.g. trastuzumab and pertuzumab)56, on the target cell, which can lead to 
cross-linking and downregulation of the targeted antigen57. A common tumor escape 
mechanism for cancer cells in antibody therapeutics is signaling through a separate 
receptor complex58-62. Targeting both the primary and secondary receptor can prevent 
downstream survival signaling, causing the cancer cells to die. Examples of such bsAbs 
are the anti-HER2/anti-HER3 dual scFv linked human serum albumin MM-11163, a two-
in-one antibody against HER3 and HER1, and istiratumab (an anti-IGF1R and anti-
HER3 bsAb)64. 
 
1.2.4 Bispecific antibodies and HER2/HER3 tumorgenesis 
The importance of bsAbs is demonstrated in HER2-expressing cancers. While 
the monoclonal antibody trastuzumab can effectively treat patients with HER2-
expressing cancers, a portion of tumors escape trastuzumab treatment through 
13 
 
dimerization of the HER2 receptor with the HER3 receptor. Trastuzumab binds to 
domain IV of the HER2 extracellular domain and does not inhibit ligand-mediated 
heterodimerization of HER2 and HER365. The HER2/HER3 complex is known to 
actively signal through the PI3K/Akt pathway, allowing the tumor to escape HER2 
signaling inhibition. bsAbs targeting both HER2 and HER334, 63, 66-68 were created to 
overcome ligand-mediated signaling of HER2/HER3 dimers. This topic is further 
addressed in Section 2 of this study.  
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1.3 Antibody-drug conjugates 
1.3.1 Overview of antibody-drug conjugates 
Cancer therapeutics have changed rapidly over the last two decades, particularly in 
the area of antibody therapy. While antibodies, such as trastuzumab, have shown initial 
therapeutic efficacy, many tumors acquire trastuzumab resistance69, 70. Monoclonal 
antibodies are often paired with chemotherapy or small molecule inhibitors to enhance their 
efficacy and to prevent tumor escape. Cytotoxic drugs, such as those used in chemotherapy, 
while potent, are not cancer cell-specific and therefore leave a narrow therapeutic window 
where a physician can safely administer the cytotoxic drug while achieving clinical 
efficacy. Antibody-drug conjugates (ADCs), however, combine the target specificity of an 
antibody with the potency of cytotoxic drugs to enhance the therapeutic window. Ideally, 
the ADC would cause much higher on-target toxicity in comparison to off-target toxicity 
(target-dependent and target independent toxicity, respectively)71. Much can still be done to 
enhance the therapeutic window, as evidenced by the low maximum tolerated dose of 
ADCs in clinical trials72, 73. 
ADCs are composed of a targeting antibody, a cytotoxic drug, and a linker that 
attaches the cytotoxic drug to the antibody (Figure 1-3). While an ADC appears simplistic 
in structure, the attachment of hydrophobic cytotoxic drugs to the antibody is challenging 
and has resulted in many failed ADCs in pre-clinical trials74. Both T-DM1 and Adcetris 
have demonstrated the efficacy of ADCs in the clinic, and with more than 50 other ADCs 
in different phases of clinical testing73, the future for ADCs seems bright. However, both 
current and upcoming ADCs suffer from short-comings in which antigens can be targeted, 
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linker technology used, and cytotoxic drugs used, which ultimately limits the therapeutic 
window. Issues such as hydrophobicity of conjugated cytotoxic drug can lead to off-target 
toxicity and limits how many cytotoxic drug molecules can be conjugated to an antibody75.  
Current methods to enlarge the therapeutic window are focused on improving the cytotoxic 
drug and linker of an ADC. These methods include using more potent cytotoxic drugs, 
masking the hydrophobic cytotoxic drug, and engineering both linker and cytotoxic drug to 
be less hydrophobic76-81. Methods involving engineering the antibody of ADCs, however, 
are in the minority82. A method of engineering acid-switched ADCs for enhancing the 





Figure 1-3. ADC schematic depicting the cytotoxic drug monomethyl auristatin E 
(MMAE) conjugated to the hinge region of an antibody with a maleimidocaproyl-valine-





1.3.2 Antibody and antigen requirements for ADCs 
Although ADCs would appear to be easily implemented to treat several diseases and 
cancers, this is not the case due to the stringent requirements that need to be met in order to 
attain ADC efficacy83. Early ADCs such as KS1/484 and BR9685, which comprise 
antibodies conjugated with methotrexate and doxorubicin, respectively, did not show any 
therapeutic activity despite significant tumor localization. The failures of these ADCs were 
attributed to all three components of the ADC. Both KS1/4 and BR96 targeted antigens 
with limited surface expression, the linkers used (a cleavable amide linker and an acid-
labile hydrazone linker for KS1/4 and BR96, respectively) were either prone to cleavage 
prior to entering the target cell or inefficient release of the drug inside the target cell, and 
lastly the cytotoxic drugs used were only moderately cytotoxic. Due to the lessons learned 
from these early ADCs, requirements for a successful ADC were outlined. 
1. The target antigen should be highly expressed on the target cell. The target 
antigen should have limited to no expression on normal cells to prevent non-
specific targeting and uptake. Furthermore, the target antigen should be readily 
accessible on the surface of the target cells.   
2.  The antibody should be rapidly internalized through receptor-mediated 
endocytosis and the receptor should not recycle back to the cell surface 
otherwise the ADC cannot be delivered into the cell. This is critical in the 
delivery of cytotoxic drugs as some ADCs must be degraded in lysosomal 
compartments of target cells to release their cytotoxic payloads. Recently, some 
groups have constructed non-internalizing ADCs86-89. While they show efficacy 
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in in vitro and in vivo rodent studies, these non-internalizing ADCs need to be 
delivered repeatedly in relatively large doses in order to obtain a therapeutic 
effect.  
 
1.3.3 Linker technology 
The linker in ADCs is responsible for the attachment of the cytotoxic drug to the 
antibody combined with the efficient release of the cytotoxic drug within the target cell. 
As the goal of ADCs is to enhance the therapeutic window of the cytotoxic drug, the 
linker is vital in determining the on-target and off-target toxicity of an ADC. A linker 
must be stable in circulation in order to prevent off-target toxicity. Release of the 
cytotoxic drug due to linker failure increases off-target toxicity and can decreases on-
target toxicity. Decreased off-target toxicity can lead to a loss in efficacy of the ADC in 
treating the target tumor and result in tumor escape. 
As mentioned above, how rapidly the target antigen is internalized is important in 
determining if an ADC specific for the target antigen should be made. Furthermore, as 
the pH drops when the antigen/ADC complex is internalized from the cell surface into 
early endosomes and trafficked into the lysosome18, 90, 91, the linker that is used critically 
determines to where and how the cytotoxic drug is delivered. Linkers used in ADCs are 
divided into two categories—cleavable and non-cleavable. 
1. Cleavable linkers are chemically or enzymatically cleaved within or near the 
target cells. These linkers include hydrazones, disulfides, and peptides.  
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a. Hydrazone linkers are hydrolyzed in the acidic environment of
endosomes to release the cytotoxic drug. However, this type of linker 
is known to have a short half-life92 . Mylotarg, the first clinically 
approved ADC, used the hydrazone linker technology but was 
withdrawn from the clinic due to lethal liver toxicity which was 
attributed to the instability of the linker. Furthermore, the tumor 
microenvironment can have an acidic pH which can lead to the 
release of the cytotoxic drug prior to ADC internalization93. 
b. Disulfide linkers are designed to be released in the reducing
conditions of endosomes after ADC internalization. These linkers rely 
on the higher concentrations of reduced glutathione within cells (1-10 
mM) in comparison to its extracellular concentrations in the blood94 
to specifically cleave disulfide bonds and release the cytotoxic drug 
within the target cell. ADCs with disulfide linkers are usually 
internalized and undergo degradation before glutathione can release 
the cytotoxic drug from the linker95, 96. 
c. Peptide linkers, such as Val-Ala and Val-Cit, rely on the enzyme
cathepsin β for cleavage within endosomes after internalization. As 
cathepsins are enzymatically active in acidic environments, such as in 
late endosomes and lysosomes, enzymatic cleavage of the peptide 
linkers in the extracellular environment is rare. Peptide linkers have 
therefore become one of the most prevalent designs for cleavable 
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linkers due to their plasma stability and specific release mechanism. 
Notably, Brentuximab Vendotin uses this technology for delivery of 
monomethyl auristatin E (MMAE). 
2. Non-cleavable linkers fully rely on ADC degradation by lysosomal 
proteases to release their cytotoxic drug into the target cell. While non-
cleavable linkers have superior plasma stability, the cytotoxic payload is 
sometimes derivatized to a less potent form in order to be conjugated to a 
non-cleavable linker97. T-DM1 uses a non-cleavable linker as prior 
iterations of T-DM1 using cleavable linkers showed lower efficacy98.  
 
1.3.4 Cytotoxic drugs 
Initially, ADCs used cytotoxic drugs that were commonly used in chemotherapy 
(e.g. methotrexate and doxorubicin) which had moderate potency. As a small fraction of 
antibody/ADC reaches the tumor site (as little as 0.003-0.08% injected dose per gram of 
tumor)99, significantly more potent cytotoxic drugs were needed to generate effective 
ADCs. Current cytotoxic drugs, such as monomethyl auristatin E (MMAE) and 
auristatins, have toxicity at nanomolar concentrations100, 101.  One method to increase 
delivery of ADC to the tumor site is to increase the ADC dose given to a patient, 
however, this can be problematic as increases in ADC delivery to normal cells can lead 
to dose-limiting toxicities. An alternative approach for enhancing drug delivery is to 
increase the drug-to-antibody ratio (DAR) of an ADC. ADCs with high DAR (DAR ≥ 
8), however, are rapidly cleared in the liver, resulting in shorter times of tumor 
20 
 
exposure75, 102. To overcome this, engineered linkers with reduced hydrophobicity are 
currently being investigated for ADCs with high DARs. 75, 103, 104. 
Cytotoxic drugs can be used to separate ADCs into two main groups. The first 
group is comprised of drugs that disrupt microtubule assembly, disassembly, and 
formation. Such anti-mitotics include dolastatin 10 analogs105, maytansinoids106, and 
tubulysins107. As microtubules play an essential role in many cellular processes, 
including cell division, drugs targeting microtubules prove to be highly cytotoxic in 
rapidly dividing cells, such as cancer cells. The second group of cytotoxic drugs 
comprises DNA targeting drugs such as duocarmycin81, calicheamicins108, and 
pyrrolobenzodiazepine dimers79.  DNA-targeting drugs cause DNA strand scission, 
alkylation or cross-linking. Unlike the anti-mitotics, the DNA-targeting drugs do not 
necessarily depend on the rapid proliferation of cancer cells and may therefore be used 
to target cancer cells with lower proliferation rates.   
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1.4 Thesis overview 
Antibody and ADC therapy targeting HER2-expressing cancers is expanding 
with the prevalence of HER2 found in multiple cancers. However, resistance to antibody 
treatment such as ligand-mediated tumor escape and a small therapeutic window for 
ADCs suggest there are still many issues to address for better therapeutic efficacy. This 
thesis presents studies that use antibody engineering to address the issues of tumor 
escape by HER2 family receptor dimerization and the inefficient delivery of cytotoxic 
drug by ADCs. The first aim focuses on the generation of a bsAb that targets both HER2 
and its favored dimerization partner, HER3, which is known to trigger potent PI3K/Akt 
signaling after binding to its ligand heregulin and undergoing receptor dimerization with 
HER2. The second aim focuses on the generation of acid-switched antibodies that bind 
tightly to HER2 at neutral pH and dissociate from HER2 under acidic conditions to take 
advantage of the acidic environment of the endosomal lumen for better trafficking of 
antibodies towards the degradative pathway in cells. The third aim characterizes the 
acid-switched antibodies before and after conjugation with the cytotoxic drug MMAE. 
Furthermore, the acid-switched ADC is assessed in vitro for the accumulation of the 





Aim 1: Analyze the efficacy of a bsAb in preventing ligand-induced resistance in HER2-
overexpressing breast cancer cells. 
A bsAb was engineered in the format of an IgG-scFv to target both HER2 and 
HER3 receptors on HER2-overexpressing breast cancer cells. This bsAb was designed to 
stop ligand-mediated HER2/HER3 dimers from causing cell-proliferative downstream 
signaling through the PI3K/Akt pathway. Immunoblots of signaling pathways and 
receptor expression were analyzed to interpret cell proliferation results after treatment 
with the bsAb. Proliferation was assayed to determine the efficacy of the bsAb in 
inhibiting cancer cell proliferation in the presence and absence of the HER3 ligand 
heregulin and the small molecule tyrosine kinase inhibitor lapatinib. 
Aim 2: Generation and characterization of acid-switched antibodies. 
An antibody that binds tightly to HER2 at neutral conditions but only weakly at 
acidic conditions is considered to be an acid-switched antibody. Antibody engineering 
techniques such as histidine scanning and phage display were used to isolate acid-
switched mutants. The acid-switched antibody was analyzed by flow cytometry, surface 
plasmon resonance, and enzyme-linked immunosorbent assay (ELISA) to characterize 
its binding behavior to HER2 at both neutral and acidic pHs. 
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Aim 3: Analysis of acid-switched antibodies as ADCs for enhanced delivery of cytotoxic 
drug to target cells. 
Stability and therapeutic efficacy are crucial determinants of the promise of acid-
switched ADCs. Acid-switched antibodies and their respective ADCs were assayed for 
stability in human serum. The ADCs were analyzed for accumulation by flow cytometry 
and for localization by fluorescence microscopy. MTS assays and mass spectrometry 
were used to analyze the dose response and release of cytotoxic drug in vitro. Mouse 
experiments were conducted to test the efficacy of the acid-switched ADC in 
comparison to T-DM1 and the wild-type ADC. 
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2. ENGINEERING MULTIVALENT ANTIBODIES TO TARGET
HEREGULIN-INDUCED HER3 SIGNALING IN BREAST CANCER 
CELLS*
2.1 Introduction 
Multiple cancers are driven by aberrant signaling through the human epidermal 
growth factor receptor (HER), also known as ErbB, family members. Recent studies 
have indicated that HER2-HER3 heterodimers can play a central role in tumorigenesis19, 
20, 109-111. HER3 is a preferred dimerization partner for HER2, which has no known 
ligand and is constitutively active20, 112, 113. Although HER3 has very low intrinsic kinase 
activity, there are six phosphorylation-dependent binding sites for PI3K on the cytosolic 
tail of this receptor114. Consequently, HER2-HER3 heterodimers are the most effective 
activators identified to date of the PI3K/Akt pathway through both ligand-independent 
and ligand-dependent signaling20, 65. Ligand-dependent activation of HER3 involves the 
binding of heregulin or other ligands to induce a conformational switch in the 
dimerization arm, driving heterodimer formation with kinase competent partners such as 
HER2 or EGFR20, 113.  
* This study has been published in the journal MAbs [Kang JC, Poovassery JS, Bansal P,
You S, Manjarres, IM, Ober RJ, Ward ES. (2014) Engineering multivalent antibodies to 
target heregulin-induced HER3 signaling in breast cancer cells. MAbs 6(2): 340-353] It 
is reprinted here with permission from the Taylor & Francis Group. 
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Consistent with HER3 as a driver of tumorigenesis, loss of HER3 expression in 
breast cancer cells results in reductions in both PI3K/Akt signaling and proliferation109, 
110. Further, modeling studies demonstrate that HER3 represents a central node in 
PI3K/Akt signaling111. In conjunction with the limited efficacy of solely targeting HER2 
with monotherapies such as trastuzumab115-117, these observations have motivated the 
development of therapeutics targeting HER3 or HER2-HER3 heterodimers19, 63, 68, 118. 
Recent data indicate that the targeting of this axis with antibodies is less effective in the 
presence of heregulin63, which is expressed in either autocrine or paracrine fashion in 
many tumor types119-121. Thus, there is a need for the generation of improved 
therapeutics directed toward ligand-dependent activation of HER3. The current study 
involves a comparison of two distinct approaches using bispecific HER2/HER3 specific 
antibodies or multivalent HER3-specific antibodies to target HER3 in the presence of the 
HER3 ligand, heregulin.  
As an alternative to targeting HER family members with antibodies, the use of 
small molecule inhibitors of the tyrosine kinase activity of EGFR or HER2, or of the 
downstream kinase, PI3K, has attracted much interest122-128. However, these inhibitors 
can lead to tumor escape due to upregulation of compensatory signaling pathways and 
complex cross-regulatory networks involving negative feedback loops. For example, the 
delivery of lapatinib, a tyrosine kinase inhibitor (TKI) that targets both EGFR and 
HER2, results in upregulation of HER2 and HER3 expression and PI3K/Akt 
signaling129-132. Lapatinib resistance pathways can also include activating mutations of 
PI3K133, and the inhibitory effects of lapatinib can be dampened by the presence of the 
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HER3 ligand, heregulin63, 134-136. This suggests that lapatinib in combination with 
antibodies or bispecifics that bind to HER3 might provide an effective route for therapy, 
particularly for tumors involving autocrine or paracrine heregulin loops that can result in 
limited efficacy of monotherapies.  
Related to the limited therapeutic efficacy of TKIs such as lapatinib that inhibit 
EGFR and HER2 activation, HER3 can associate with other activating receptors such as 
cMET and insulin-like growth factor type I receptor I/insulin receptor substrate-120, 112, 
137, 138. A possible strategy to extinguish HER3-PI3K signaling would therefore be to 
inhibit multiple potential HER3 partners. This provides the impetus for directly targeting 
HER3, which would avoid the complexity of identifying and globally inhibiting all 
HER3 partners. Here, we have taken the approach of investigating the ability of a 
bispecific anti-HER2/HER3 antibody to drive HER3 into HER2-HER3 heterodimers 
that, through combination treatment with lapatinib, are “kinase-dead”. Locking HER3 
into such inactive complexes is expected to sequester this receptor from interactions with 
other signaling competent partners and, as such, have anti-tumor effects.  
A second route toward extinguishing HER3 signaling is to develop strategies to 
induce the efficient internalization and degradation of this receptor. In support of this 
approach, several studies have demonstrated that reduction of HER3 expression has anti-
proliferative effects109, 110. HER3 is constitutively internalized into the endolysosomal 
pathway139 and it is well documented that receptor crosslinking leads to downregulation 
in multiple different cellular systems. We therefore reasoned that a multivalent 
(tetrameric) anti-HER3 antibody would induce more efficient HER3 internalization or 
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degradation relative to its bivalent counterpart, thereby enhancing clearance from the 
cell surface. The efficacy of this approach has been compared with that of recruiting 
HER3 into kinase-inactivated HER2-HER3 heterodimers. These comparative studies 
have also been extended to microscopy analyses of the trafficking behavior of the 
different antibodies within cells, which relates to both drug delivery for antibody-drug 
conjugates and Fc-mediated cytotoxicity140, 141.  
Our study has led to several observations that are of relevance to targeting HER3. 
First, we show that in the presence of heregulin, combination treatment with antibodies 
and lapatinib is necessary to achieve inhibition of signaling and growth. Under these 
conditions, a tetravalent HER3-specific antibody induces increased degradation of HER3 
and has more potent anti-tumor effects relative to its bivalent counterpart. Importantly, 
when used in combination with lapatinib, the bispecific anti-HER2/ HER3 antibody is a 
more effective inhibitor of heregulin-driven signaling and growth compared with anti-
HER3 antibodies, tetravalent anti-HER3 antibodies or mixtures of individual antibodies 
specific for HER2 and HER3. Our observations are consistent with a model in which the 
bispecific antibody recruits HER3 into HER2-HER3 heterodimers that are inactive in the 
presence of lapatinib. Collectively, these studies provide support for the combined use of 
multimeric anti-growth factor receptor antibodies with small molecule TKIs for the 





2.2.1 Antibodies specific for HER2 and HER3 have differential effects on signaling and 
proliferation 
The anti-HER3 antibody, Ab6 (MM-12119), which competes with heregulin for 
binding to HER3, was generated in our laboratory as a biosimilar and used throughout 
these studies. To investigate whether a tetravalent anti-HER3 antibody is more effective 
than its bivalent counterpart in inhibiting cell growth and proliferation, we fused the Ab6 
single chain variable fragment (scFv) to the CH3 domains of Ab6 via a Gly-Ser-Ser 
linker (Ab6tet). In addition, a bispecific trastuzumab (anti-HER2)-Ab6 antibody (TAb6) 
and a bispecific pertuzumab (anti-HER2)-Ab6 antibody (PAb6) were generated by 
fusing scFv fragments corresponding to Ab6 to the CH3 domains of trastuzumab and 
pertuzumab, respectively, using an analogous design (Fig. 2-1). All antibodies were 
expressed in transfected Chinese hamster ovary (CHO) cells. The expression yields of 
the bispecific antibodies were 4.5 mg/L, 2.5 mg/L, and 8 mg/L for Ab6tet, PAb6 and 
TAb6, respectively. Size exclusion and serum stability analyses of the bispecific proteins 
are presented in the Supplementary Materials (Fig. 2-2 and 2-3). For comparative 
purposes, size exclusion studies of Ab6, trastuzumab and pertuzumab are shown (Fig. 2-
2). Ab6 and the bispecific antibodies also bound to immobilized, recombinant Fc-HER2 
(TAb6, PAb6) or HER3 (Ab6, Ab6tet, TAb6, PAb6) in surface plasmon resonance 
experiments (BIAcore; data not shown). The in vivo half-lives (β-phase) of Ab6tet and 
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TAb6 were also determined in BALB/c SCID mice and were 228 ± 14 (n = 4 mice) and 




Figure 2-1. Schematic representation of the bispecific antibody  (TAb6) comprising 







Figure 2-2. Analysis of trastuzumab, pertuzumab, Ab6, bispecific trastuzumab with anti-
HER3 Ab6 scFv (TAb6), bispecific pertuzumab with anti-HER3 Ab6 scFv (PAb6), and 
tetrameric anti-HER3 (Ab6tet) using HPLC and size exclusion chromatography. 
Trastuzumab, pertuzumab, TAb6, and PAb6 were analyzed using a Yarra 3U SEC-3000 
column, whereas a Hiload 16/600 Superdex 200pg column was used for Ab6 and Ab6tet. 
The major peak runs at the expected size for either an antibody homodimer (150 kDa) or 





Figure 2-3. Serum stability analyses of the bispecific trastuzumab with anti-HER3 Ab6 
scFv (TAb6), bispecific pertuzumab with anti-HER3 scFv (PAb6), and tetrameric anti-
HER3 (Ab6tet). Antibodies were incubated in mouse serum for 0, 3, or 6 days at 37ºC, 
diluted into PBS to concentrations of 0.83 or 0.50 nM, and analyzed by sandwich 
ELISA. Differences were not significant for comparisons of 0 and 6 day samples (P 
value > 0.05; Student’s t-test). 
 
We initially assessed the effect of targeting HER3 and HER2/HER3 with several 
different antibody formats in the absence of the HER3 ligand, heregulin. For 
comparative purposes we also included the anti-HER2 antibodies, trastuzumab and 
pertuzumab, which bind to domain IV and the dimerization arm (domain II), 
respectively, of HER2142, 143. The anti-HER3 antibody, Ab6, and its tetrameric form, 
Ab6tet, reduced proliferation in the HER2-overexpressing cancer cell lines, SK-BR-3 
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and HCC1419 (Fig. 2-4A). Although Ab6 and Ab6tet treatment resulted in a trend 
toward reduced proliferation in BT-474 cells, the effects were not significant. By 
contrast with SK-BR-3 and HCC1419 cells, BT-474 cells express a gain of function 
variant of PI3K144, 145 which could account for the reduced efficacy of anti-HER3 
antibodies. Consistent with the observations of others146, trastuzumab has higher anti-
proliferative activity on ligand-independent growth of SK-BR-3 and BT-474 cells 
relative to pertuzumab (Fig. 2-4A). A mixture of pertuzumab and Ab6 is also less 
effective than trastuzumab and Ab6.  
Although combinations of anti-HER2 and anti-HER3 antibodies (Ab6 combined 
with trastuzumab or pertuzumab) had anti-proliferative activities, exposure of cells to the 
bispecific, TAb6, comprising trastuzumab plus Ab6, resulted in increased proliferation 
(Fig. 2-4A). Further, the bispecific antibody comprising Ab6 and pertuzumab (PAb6) 
induced proliferation (Fig. 2-4A). The effects of both PAb6 and TAb6, which bind to 
different sites of HER2142, 143, indicate that proximity of HER2 and HER3 is sufficient 
for proliferative signaling, rather than a need for the receptors to dimerize in a specific 
configuration. This proximity model is also consistent with the observation that exposure 
of cells to a mixture of trastuzumab or pertuzumab and Ab6, which would not be 
expected to drive formation of HER2-HER3 heterodimers, results in reduced 




Figure 2-4. Effects of antibodies specific for HER2 and/or HER3 on HER2-
overexpressing breast cancer cells. (A) Cells were incubated with 50 nM anti-HER3 
(Ab6), tetrameric anti-HER3 (Ab6tet), trastuzumab (T), pertuzumab (P), trastuzumab or 
pertuzumab and Ab6 (T + Ab6 or P + Ab6), bispecific trastuzumab with anti-HER3 Ab6 
scFv (TAb6), or bispecific pertuzumab with anti-HER3 Ab6 scFv (PAb6) for 5 d. 
Proliferative responses were assessed using the MTS reagent and were normalized 
against the proliferation of cells incubated in medium (Med) only. Data shown are 
means of triplicates ± standard deviation. The symbols * and ** indicate significantly 
lower or higher proliferative responses, respectively, between cells treated with antibody 
and PBS vehicle (Student t-test; P < 0.05). (B) SK-BR-3 or BT-474 cells were treated 
with anti-HER2/HER3 antibodies (50 nM) for 1 or 24 h, and cell lysates analyzed by 
immunoblotting. Data shown are representative of at least two independent experiments. 
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Analyses of the effects of the antibodies on the phosphorylation of HER3, Akt 
and Erk demonstrated that the anti-proliferative effects are associated with decreased 
pAkt levels in SK-BR-3 and BT-474 cells (Fig. 2-4B). Although pErk levels were lower 
following treatment of cells for one hour with Ab6, Ab6tet, or Ab6 combined with anti-
HER2 antibodies than for cells treated with trastuzumab, pertuzumab, TAb6 or PAb6, 
these differences were not sustained at the 24 h time point (Fig. 2-4B). Exposure of SK-
BR-3 or BT-474 cells to TAb6 or PAb6 resulted in increased pAkt (S473) levels that 
persisted for at least 24 h, consistent with the pro-proliferative effects of these bispecific 
antibodies. By contrast, the levels of pAkt at 24 h were decreased in cells treated with 
any of the other antibodies or antibody combinations (Fig. 2-4B). Pertuzumab as a single 
agent, or in combination with Ab6, was less effective than trastuzumab (with or without 
Ab6) in reducing pAkt (S473) phosphorylation, which is congruent with the lower anti-
proliferative activity of this antibody (Fig. 2-4A).  
Earlier studies have shown that relief of feedback inhibition of the FoxO1/3a 
transcription factors can lead to upregulation of multiple receptor tyrosine kinases such 
as HER3 and insulin-like growth factor-1 receptor (IGF-1R) and subsequent reactivation 
of Akt130, 147, 148. However, the possibility of pAkt reactivation occurring in the current 
study following treatment of cells with the bispecific antibodies, TAb6 or PAb6, can be 
excluded by the relatively rapid kinetics of pAkt induction observed (1 h, Fig. 2-4B). To 
further support this, we observed phosphorylation of Akt following 15 min of exposure 





Figure 2-5. The bispecific anti-HER2/HER3 antibodies, TAb6 and PAb6, induce 
phosphorylation of Akt and HER3 within 15 minutes. SK-BR-3 and BT-474 cells were 
treated with 50 nM anti-HER3 (Ab6), tetrameric anti-HER3 (Ab6tet), trastuzumab (T), 
pertuzumab (P), trastuzumab and Ab6 (T + Ab6), pertuzumab and Ab6 (P + Ab6), 
bispecific trastuzumab with anti-HER3 Ab6 scFv (TAb6) or bispecific pertuzumab with 




Total HER3 levels in the cells following treatment with anti-HER3 antibodies 
were also analyzed. In general, HER3 levels were reduced by treatment with anti-HER3 
antibodies, Ab6 and Ab6tet, whereas exposure of cells to the bispecific antibodies, TAb6 
and PAb6, resulted in less HER3 degradation (P < 0.05; Fig. 2-4B; Fig. 2-6). Reduced 
HER3 degradation following TAb6 or PAb6 treatment is consistent with the inhibitory 
effects of HER2 expression on the internalization of ligand-activated EGFR or HER3149, 
150. The increased HER3 degradation induced by Ab6tet relative to Ab6 was more 
marked for SK-BR-3 than BT-474 cells, although in both cases the differences were 





Figure 2-6. The multivalent anti-HER3 antibody, Ab6tet, induces higher levels of HER3 
degradation compared with the bivalent counterpart, Ab6, and bispecific TAb6. SK-BR-
3 cells were treated with 50 nM anti-HER3 antibody (Ab6), Ab6tet, bispecific 
trastuzumab with anti-HER3 Ab6 scFv (TAb6), or PBS vehicle for 3 or 9 hours. Cell 




Microscopy analyses were used to further investigate the intracellular trafficking 
pathways taken by Ab6, Ab6tet and TAb6 (Fig. 2-7). These studies demonstrate that 
Ab6tet is internalized into EEA-1 positive early endosomes more rapidly than Ab6, and 
enters these compartments within 5 min of treatment. Following 15 min of treatment, 
both Ab6 and Ab6tet are internalized into early endosomes, although the levels of Ab6 
remaining on the plasma membrane are greater than for Ab6tet (Fig. 2-7). By contrast, 
the majority of TAb6 is present on the plasma membrane following 5–60 min of 
treatment (Fig. 2-7; Fig. 2-8). Within 60 min of treatment, Ab6 and Ab6tet are present in 
LAMP-1+ lysosomes (Fig. 2-8). Multivalent antibody binding to HER3 therefore 
enhances the rate of HER3 internalization into the endolysosomal pathway, consistent 





Figure 2-7. Ab6tet internalizes into SK-BR-3 cells more rapidly than Ab6. Cells were 
pulsed with 50 nM anti-HER3 (Ab6), tetrameric anti-HER3 (Ab6tet) or bispecific 
trastuzumab with anti-HER3 Ab6 scFv (TAb6) for 5 minutes at 37°C, chased for 0, 10 or 
20 minutes, fixed, permeabilized and stained with anti-EEA-1 antibody. The combined 
pulse plus chase times are indicated on the left margin. Anti-HER3 or HER2/HER3 
antibodies were detected with Alexa 555-labeled secondary antibody (pseudocolored red 
in overlay) and anti-EEA-1 antibody with Alexa 647-labeled secondary antibody 
(pseudocolored green in overlay). Yellow arrows in the images for Ab6tet-treated cells 
indicate examples of internalized Ab6tet that is associated with EEA-1 positive 





Figure 2-8. The bivalent anti-HER3 antibody, Ab6, and its multivalent counterpart, 
Ab6tet, traffic into LAMP-1 positive endosomal structures within one hour of treatment. 
SK-BR-3 cells were treated with 50 nM Ab6, Ab6tet, or bispecific trastuzumab with 
anti-HER3 scFv Ab6 (TAb6) for 15 minutes at 37 °C and chased in medium for 45 
minutes at 37 °C. Cells were fixed, permeabilized and stained for LAMP-1. Anti-HER3 
or HER2/HER3 antibodies were detected with Alexa 555-labeled secondary antibody 
(pseudocolored red in overlay) and anti-LAMP-1 antibody with Alexa 488-labeled 
secondary antibody (pseudocolored green in overlay). Examples of co-localization of 




2.2.2 Targeting HER2/HER3 with antibodies is ineffective in the presence of heregulin 
Heregulin is frequently present in tumors due to autocrine or paracrine 
production119-121, motivating an investigation of the effects of the antibodies on tumor 
cell growth in the presence of this HER3 ligand. HCC1419 cells showed increased 
proliferation in the presence of heregulin, whereas reduced proliferation was observed 
for SK-BR-3 cells (Fig. 2-9A). Although BT-474 cells showed a trend toward heregulin-
stimulated proliferation, differences between vehicle- and heregulin-treated cells were 
not always significant. Reduced proliferation of SK-BR-3 cells in response to heregulin 
has been described previously151. Heregulin exposure ablated the inhibitory effects of 
Ab6, Ab6tet, trastuzumab or trastuzumab plus Ab6 on ligand-independent proliferation 
of BT-474 or HCC1419 cells (Fig. 2-4A and 2-9A). Slightly higher proliferation of 
HCC1419 cells was observed following TAb6 relative to trastuzumab plus Ab6 
treatment, but differences for these two treatments were not significant for SK-BR-3 and 
BT-474 cells.  
The reduced efficacy of the antibodies in the presence of heregulin was 
accompanied by either no change (SK-BR-3 cells with trastuzumab and TAb6 24 h 
following treatment and BT-474 cells with all treatments), or a reduction (SK-BR-3 cells 
with Ab6, Ab6tet, or a mixture of trastuzumab plus Ab6 at 24 h) in pAkt levels (Fig. 2-
9B). Collectively, the data indicate that antibody targeting of HER2 and HER3 has 





Figure 2-9. Antibodies specific for HER2 and/or HER3 have reduced efficacy in 
inhibiting proliferation and PI3K/Akt signaling in the presence of heregulin. A, Cells 
were incubated with heregulin (HRG, 6.25 nM) and 50 nM anti-HER3 (Ab6), tetrameric 
anti-HER3 (Ab6tet), trastuzumab (T), trastuzumab and Ab6 (T + Ab6) or bispecific 
trastuzumab with anti-HER3 Ab6 scFv (TAb6) for 5 days. Proliferative responses were 
assessed using the MTS reagent and were normalized against the proliferation of cells 
incubated in medium (Med) only. Data shown are means of triplicates ± standard 
deviation. * indicates statistically significant differences between proliferative responses 
for cells treated with antibody in the presence of heregulin and cells treated with 
heregulin only (Student’s t-test; P < 0.05). B, SK-BR-3 or BT-474 cells were treated 
with anti-HER2/HER3 antibodies (50 nM) in the presence of 6.25 nM heregulin for 1 or 
24 hours, and cell lysates analyzed by immunoblotting. Data shown are representative of 








2.2.3 Lapatinib combined with antibodies specific for HER2/HER3 overcomes 
heregulin-mediated resistance 
The induction of proliferative signaling by HER2-HER3 dimerization “forced” 
by TAb6 treatment suggested that the combination of this bispecific antibody with the 
small molecule inhibitor of HER2 (and EGFR) kinase activity, lapatinib, might stabilize 
HER2-HER3 heterodimers in an inactive state. Further, we hypothesized that such 
42 
 
complexes would preclude the interaction of HER3 with signaling competent partners. 
Lapatinib treatment is known to result in upregulation of HER2 and HER3 levels on the 
plasma membrane129, 132, and we confirmed these observations under the conditions of 
our assay (except that HER2 was not upregulated on BT-474 cells; Fig. 2-10). Treatment 
of SK-BR-3 and BT-474 cells with lapatinib at doses ranging from 50 nM–1 μM resulted 
in inhibition of proliferation (Fig. 2-11A). However, this growth inhibition was ablated 
by exposure of cells to heregulin (Fig. 2-11A). Although lapatinib treatment alone 
resulted in potent inhibition of HER3, Akt and Erk phosphorylation, this was partially 





Figure 2-10. Lapatinib treatment induces upregulation of HER2 and HER3 (SK-BR-3) 
or HER3 (BT-474) levels on the plasma membrane of breast cancer cells. Cells were 
treated with 1 µM lapatinib (Lap), medium (Med) or vehicle control (DMSO) for 24 
hours. Cell surface HER2 or HER3 was detected by incubation with 50 nM Alexa 488-
labeled trastuzumab or Alexa 647-labeled Ab6 followed by flow cytometric analyses. 
Data shown represent means of mean fluorescence intensities ± standard deviation of 
triplicate samples following subtraction of background fluorescence intensities. * 
indicates statistically significant differences between lapatinib and DMSO (vehicle) 







Figure 2-11. Heregulin treatment reverses the anti-proliferative effects of lapatinib in 
HER2 overexpressing cell lines. A, cells were incubated with different concentrations of 
lapatinib (L) in the presence and absence of heregulin (HRG; 6.25 nM) for 5 days. 
Proliferative responses were assessed using the MTS reagent and were normalized 
against the proliferation of cells incubated in medium (Med) only. Data shown are 
means of triplicates ± standard deviation. * indicates statistically significant differences 
between proliferative responses for cells treated with lapatinib and DMSO vehicle 
(Student’s t-test; P < 0.001). B, SK-BR-3 or BT-474 cells were treated with 1 µM 
lapatinib (Lap) in the presence and absence of heregulin (6.25 nM) for 1 or 24 hours, and 
cell lysates analyzed by immunoblotting. Data shown are representative of at least two 









The observation that lapatinib alone has limited efficacy in blocking cell 
proliferation in the presence of heregulin prompted us to investigate the effect of 
combination treatment of heregulin-exposed SK-BR-3, BT-474 and HCC1419 cells with 
lapatinib and HER3-targeting antibodies. Addition of Ab6 or Ab6tet to lapatinib resulted 
in anti-proliferative effects compared with the effects of lapatinib alone (Fig. 2-12A). In 
addition, for SK-BR-3 and HCC1419 cells, Ab6tet was more effective than Ab6 (Fig. 2-
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12A). Consistent with the inability of trastuzumab to inhibit ligand-dependent HER2-
HER3 signaling146, this HER2-specific antibody did not reduce proliferation in the 
presence of heregulin and lapatinib. By contrast, of the antibodies/bispecifics tested, the 
anti-HER2/HER3 bispecific, TAb6, was the most potent of the antibodies tested in 
combination with lapatinib in reducing proliferation of heregulin-treated cells (Fig. 2-
12A). Importantly, this bispecific also had increased anti-proliferative effects relative to 
a mixture of trastuzumab and Ab6 (Fig. 2-12A). Trastuzumab has superior activity over 
pertuzumab in inhibiting ligand-independent activity146 (Fig. 2-4), suggesting that TAb6 
would more effectively target both ligand-dependent (heregulin) and ligand-independent 
signaling than PAb6. In combination with the lower expression yield of PAb6 relative to 
that of TAb6 (2.5 mg/L vs. 8 mg/L), we therefore focused on the use of TAb6 in the 
lapatinib/bispecific combination studies. In the absence of heregulin, none of the 





Figure 2-12. The bispecific anti-HER2/HER3 antibody, TAb6, has the highest activity in 
reducing cell proliferation and PI3K/Akt signaling in the presence of heregulin and 
lapatinib. A, cells were incubated with 1 µM lapatinib (L) in the presence of heregulin 
(HRG; 6.25 nM) and treated with 50 nM anti-HER3 (Ab6), tetrameric anti-HER3 
(Ab6tet), trastuzumab (T), trastuzumab and Ab6 (T + Ab6) or bispecific trastuzumab 
with anti-HER3 Ab6 scFv (TAb6) for 5 days. Proliferative responses were assessed 
using the MTS reagent and were normalized against the proliferation of cells incubated 
in medium (Med) only. Data shown are means of triplicates ± standard deviation. * 
indicates statistically significant differences between proliferative responses for cells 
treated with antibodies vs. vehicle in the presence of lapatinib and heregulin (Student’s t-
test; P < 0.05). ** indicates statistically significant differences between proliferative 
responses for the pairwise comparison of the two indicated treatments (horizontal bars). 
B, SK-BR-3 or BT-474 cells were treated with lapatinib (Lap), heregulin (6.25 nM) and 
anti-HER2/HER3 antibodies (50 nM) as indicated for 1 or 24 hours, and cell lysates 
analyzed by immunoblotting. Data shown are representative of at least two independent 








Figure 2-13. Antibodies specific for HER2 and/or HER3 do not increase the anti-
proliferative effect of lapatinib. SK-BR-3, BT-474, and HCC1419 cells were treated 1 
µM lapatinib (L) alone or lapatinib in combination with 50 nM anti-HER3 (Ab6), 
tetrameric anti-HER3 (Ab6tet), trastuzumab (T), trastuzumab and Ab6 (T + Ab6) or 
bispecific trastuzumab with anti-HER3 Ab6 scFv (TAb6) for 5 days. Proliferative 
responses were assessed using the MTS reagent and were normalized against the 
proliferation of cells incubated in medium (Med) only. Data shown are means of 





In the presence of lapatinib and heregulin, Ab6tet, trastuzumab plus Ab6 or 
TAb6 treatment resulted in lower levels of pHER3, pErk and pAkt (S473, T308) for SK-
BR-3 and HCC1419 cells (Fig. 2-12B; Fig. 2-14). The improved activity of Ab6tet 
compared with Ab6 in SK-BR-3 and HCC1419 cells is consistent with the increased 
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degradation of HER3 in the presence of the tetrameric antibody (P < 0.05; Fig. 2-14 and 
2-15). TAb6 was the most potent antibody in reducing downstream signaling in SK-BR-
3, BT-474 and HCC1419 cells, and was more inhibitory than mixtures of trastuzumab 
and Ab6 (Fig. 2-12B; Fig. 2-14). Further, TAb6 was the only antibody in combination 
with lapatinib that reduced heregulin-induced pAkt and pErk in BT-474 cells. 
Collectively, the data indicate that in the presence of lapatinib the bispecific antibody, 





Figure 2-14. The bispecific anti-HER2/HER3 antibody, TAb6, has the highest activity in 
reducing PI3K/Akt signaling in HCC1419 cells in the presence of heregulin and 
lapatinib. Cells were treated for 24 hours with 1 µM lapatinib (Lap), 6.25 nM heregulin 
(HRG) and 50 nM anti-HER3 (Ab6), tetrameric anti-HER3 (Ab6tet), trastuzumab (T), 
trastuzumab and Ab6 (T + Ab6) or bispecific trastuzumab with anti-HER3 Ab6 scFv 





Figure 2-15. The multivalent anti-HER3 antibody, Ab6tet, induces higher levels of 
HER3 degradation compared with the bivalent counterpart, Ab6, in the presence of 
heregulin (HRG) and lapatinib (Lap). SK-BR-3 cells were treated as indicated with 
combinations of 1 µM lapatinib, 6.25 nM heregulin, 50 nM anti-HER3 (Ab6) or 
tetrameric anti-HER3 (Ab6tet) for 3 or 6 hours. Cell lysates were analyzed for total 





The limitations of targeting individual components of the HER3/PI3K/Akt 
signaling axis, including the activity of the preferred dimerization partner HER2, is well 
documented. Several factors contribute to the poor efficacy of this approach: first, 
antibodies specific for HER2 and HER3 have reduced activity in inhibiting proliferation 
and signaling in the presence of the HER3 ligand heregulin63, 134, 135 (this study), which is 
expressed in multiple tumor types119-121. Second, the use of small molecule TKIs such as 
lapatinib or gefitinib results in compensatory HER2 and HER3 upregulation and 
signaling through either incomplete blockade of HER2 kinase activity or HER3 
association with other signaling competent partners20, 112, 129-132, 137, 138. Third, these 
compensatory effects are exacerbated by the presence of heregulin63, 134-136. 
Consequently, TKIs such as lapatinib are ineffective as single agents in inhibiting breast 
tumor cell proliferation, indicating a need for the development of combination 
therapies63, 129-132.  
In the current study, we analyzed the efficacy of two HER3-focused strategies 
directed toward reducing breast cancer cell signaling and proliferation. These approaches 
also have broader relevance to the targeting of other cell surface receptors, and involve 
the use of distinct antibody designs to recruit HER3 into kinase-inhibited HER2-HER3 
complexes or induce HER3 degradation. We demonstrate that the recruitment of HER3 
into lapatinib-inactivated HER2-HER3 complexes by a bispecific anti-HER2/HER3 
antibody (TAb6, comprising trastuzumab and an anti-HER3 scFv) is efficacious in both 
ablating PI3K/Akt signaling and reducing tumor cell proliferation in the presence of 
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heregulin. Importantly, and of direct relevance to therapy, the bispecific antibody is a 
more potent inhibitor of signaling and growth than either HER2- or HER3-specific 
antibodies alone or a mixture of antibodies of both specificities. In a second approach, 
we compared the effect on tumor cell signaling and growth of a multivalent anti-HER3 
antibody (Ab6tet) that is designed to enhance HER3 degradation with its bivalent 
counterpart, Ab6. In the presence of heregulin and lapatinib, Ab6tet has higher activity. 
By comparison with bivalent Ab6, this multivalent construct induces more rapid HER3 
internalization into early endosomes. By contrast, the bispecific TAb6 induces less 
HER3 degradation than either Ab6 or Ab6tet, and yet is more effective in reducing cell 
signaling and proliferation. This indicates that the internalization resistance or recycling 
behavior of HER2149, 150 has a dominant effect on HER3 in the forced HER2-HER3 
heterodimers. Further, the internalization resistance is consistent with earlier studies in 
which endocytic uptake of EGFR or HER3 is reduced by dimerization with HER2149, 150. 
Importantly, our data indicate that the locking of HER3 into inactive HER2-HER3 
complexes, even if they remain on the plasma membrane, is a more effective strategy for 
the ablation of heregulin-mediated signaling than induction of increased HER3 
degradation.  
The question arises as to why the anti-HER3 antibody, which competes for 
heregulin binding19, is not as effective either alone or in combination with trastuzumab 
as the bispecific antibody, TAb6, in reducing HER3-PI3K signaling. In addition to 
locking HER3 into dimers, TAb6 would be expected to enhance the avidity of binding of 
Ab6 to HER3 through bridging of trastuzumab-HER2 complexes. The trastuzumab-
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HER2 interaction is of very high affinity (100 pM)3, and this, combined with high HER2 
expression levels on the cell surface, should increase avidity effects. Further, although 
Ab6tet is expected to bind with increased avidity over Ab6 through increased valency, 
the Ab6-HER3 interaction is of lower affinity (0.8 nM)111. Thus, the improved efficacy 
of Ab6tet relative to Ab6 could be due to both increased degradation of HER3 and 
higher avidity binding, but the avidity enhancement resulting from multivalent binding 
would be lower than that for TAb6.  
The use of bispecific antibodies of different formats is an active area in the 
development of cancer therapeutics152. For example, strategies to target both HER2 and 
HER3 using several different bispecific antibody formats or mixtures of antibodies have 
been described63, 68, 118. Of relevance to the use of bispecifics, however, we observe that 
in the absence of lapatinib (and heregulin), exposure of SK-BR-3, BT-474 or HCC1419 
cells to bispecific antibodies comprising either trastuzumab or pertuzumab and the anti-
HER3 scFv, Ab6 (TAb6 or PAb6, respectively), results in increased PI3K/Akt signaling 
and proliferation. The possibility that this activation is due to relief of feedback 
inhibition of the FoxO1/3a transcription factors, leading to upregulation of multiple 
receptor tyrosine kinases such as HER3 and IGF-1R130, 147, 148, is excluded by the rapid 
kinetics of pAkt induction (15 min). The observation that bispecifics containing either 
trastuzumab (TAb6) or pertuzumab (PAb6) are both active in inducing HER3 
phosphorylation and PI3K/Akt signaling suggests that proximity rather than a specific 
configuration of HER2 and HER3 is sufficient for HER3 transphosphorylation. This is 
consistent with our observation that bispecific HER2/HER3 specific antibodies can 
55 
 
sequester HER3 into HER2-HER3 heterodimers that, if inhibited by HER2-specific 
TKIs, effectively silence HER3.  
We also characterized the effect of using antibodies of different designs on 
intracellular trafficking. The increased internalization and trafficking to lysosomes 
induced by using a multivalent anti-HER3 antibody (Ab6tet) suggests that this approach 
could be used to enhance the activity of antibody-drug conjugates for which lysosomal 
delivery is required141. By contrast, a high proportion of the bispecific, TAb6, persists on 
the plasma membrane where it is exposed for recognition by FcγRs or complement 
receptors, allowing antibody dependent cell-mediated cytotoxicity/phagocytosis 
(ADCC/ADCP) or complement-mediated cytotoxicity by appropriate effector cells140.  
Earlier studies have demonstrated that dual targeting of HER2 and HER3, using 
either bispecific scFvs or mixtures of individual antibodies specific for HER2 and 
HER3, reduces tumor cell growth in the presence of lapatinib63, 118. Significantly, we 
demonstrate that TAb6 is more effective than mixtures of trastuzumab and Ab6. This is 
consistent with the concept that TAb6 anchors HER3 into lapatinib-inactivated HER2-
HER3 dimers, thereby sequestering it from interactions with other kinase competent 
partners and enabling Ab6 to bind to HER3 with increased avidity. By analogy with our 
observations, the use of a bispecific scFv-human albumin fusion (MM-111) has been 
shown to have anti-tumor effects in the presence of heregulin that were increased by the 
addition of lapatinib63, although the efficacy of MM-111 was not directly compared with 
that of anti-HER2 or anti-HER3 antibodies of the same specificities as those present in 
MM-111. Further, and by contrast with this earlier report, we observe lower levels of 
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heregulin-induced proliferation and, for most conditions or cell lines, no significant anti-
proliferative effects of monotherapy with lapatinib or trastuzumab in the presence of 
heregulin. These apparent discrepancies may be due to differences in assay conditions, 
such as the addition of heregulin following antibody treatment63 rather than simultaneous 
addition as used in the current study.  
An important difference between the activity of TAb6 and MM-111 is that, in the 
absence of heregulin and lapatinib, MM-111 does not induce proliferation63. The design 
of TAb6 and MM-111 differs in several respects: first, the scFvs specific for HER2 and 
HER3 in MM-111 are distinct from those in TAb6. Although both the anti-HER3 scFv 
(H3153) and Ab6 compete with heregulin for binding to HER3, this does not exclude the 
possibility that the two antibodies recognize distinct epitopes. The HER2-specific scFv, 
B1D2, binds to an epitope that does not overlap with trastuzumab63, 154. Second, TAb6 
has two anti-HER2 and two anti-HER3 Fabs/Fvs per molecule, whereas MM-111 has 
one scFv of each specificity. Tetravalency is expected to enhance the avidity of the 
interaction with HER2/HER3. Third, TAb6 has an antibody Fc region whereas the scFvs 
in MM-111 are linked to albumin, resulting in variations in the “span” distance of the Fv 
components of the two constructs. One or more of these factors could contribute to the 
different activities of MM-111 compared with TAb6. Significantly, the presence of an 
Fc region in TAb6 confers effector function activities such as ADCC. The surface 
retention of targeting antibodies such as TAb6 is expected to enhance ADCC and other 
cell-mediated cytotoxicity pathways, which in turn could enhance anti-tumor activity140.  
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Other multivalent antibody-based or designed ankyrin repeat proteins (DARPins) 
that target HER2 or HER3 have been recently described64, 155, 156. Specifically, a 
tetravalent antibody (MM-141), with a similar design to TAb6 in the current study, that 
targets both HER3 and IGF-1R has been shown to have anti-proliferative effects both in 
vitro and in vivo64. Analogously to our observations using TAb6 in combination with 
lapatinib, MM-141 is more effective in reducing tumor cell signaling and growth than 
mixtures of the individual antibodies of the corresponding specificities. However, MM-
141 may not be as effective as TAb6 in targeting HER2-overexpressing tumors, given 
the importance of the HER2/HER3 signaling axis in such malignancies. In the context of 
targeting HER2, a divalent anti-HER2 DARPin has been optimized to “lock” HER2 into 
an inactive dimeric configuration on the cell surface156. This DARPin-based construct 
represents a notable expansion to the possible types of molecular approaches for 
targeting HER2-addicted tumors.  
Future experiments will be directed toward analyzing the anti-tumor activity of a 
combination of lapatinib and our lead antibody, TAb6, in tumor-bearing mice. Earlier 
studies using lapatinib with the bispecific anti-HER2/HER3 antibody, MM-111, 
indicated that weekly dosing of antibody with daily lapatinib was unexpectedly more 
effective than MM-111 delivery every three days with daily lapatinib63. This indicates 
that the dosing regimen of lapatinib and TAb6, which has a longer in vivo persistence 
than MM-11163, will require optimization. Collectively, we compared the effects of 
targeting HER2, HER3 or both receptors with several different antibody formats on the 
proliferation and signaling of breast cancer cell lines. These studies demonstrate that in 
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the presence of the TKI inhibitor, lapatinib, a bispecific anti-HER2/HER3 antibody has 
higher activity than individual (multivalent) antibodies specific for HER2 and HER3 in 
inhibiting heregulin-induced signaling through the PI3K/Akt pathway and cell 
proliferation. These observations suggest that the use of such bispecifics in combination 
therapy with lapatinib to sequester HER3 into inactive heterodimers may provide an 





2.4 Materials and methods 
2.4.1 Cell lines and reagents 
The human breast cancer cell lines BT-474 and SK-BR-3 were obtained from the 
American Type Culture Collection (ATCC, catalog nos. HTB-20 and HTB-30, 
respectively) and cultured in Hybricare Medium (ATCC, catalog no. 46-X) and McCoy 
5a (Gibco, catalog no. 12330–031/Hyclone, catalog no. SH30200.01), with 1% 
penicillin/streptomycin and 10% FCS, respectively. The human breast cancer cell line 
HCC1419 (a generous gift of Drs Adi Gazdar, John Minna, and Kenneth Huffman, 
Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern 
Medical Center at Dallas, Dallas, Texas) was cultured in RPMI 1640 with 1% penicillin/ 
streptomycin and 5% FCS. For imaging experiments, cells were cultured in phenol-red 
free DMEM (Gibco, catalog no. 31053–028) supplemented with 1% 
penicillin/streptomycin, 1% L-Glutamine, 10 mM HEPES buffer, 1 mM sodium 
pyruvate, 100 nM MEM non-essential amino acids, 55 nM 2-mercaptoethanol and 10% 
FCS. Polyclonal antibodies specific for phospho-Akt-T308 (catalog no. 9275S), Akt, 
phospho-Erk1,2 (catalog no. 9101S), Erk1,2 (catalog no. 9102S), phospho-HER2 
Y1221/1222 (catalog no. 2249S), and monoclonal antibodies against phospho-Akt-S473 
(D9E) (catalog no. 4060L), and phospho-HER3 Y1289 (D1B5) (catalog no. 2842) were 
obtained from Cell Signaling Technologies. Polyclonal anti-HER3 antibody (C-17) 
(catalog no. SC-285) was from Santa Cruz Biotechnology and monoclonal anti-c-erbB2 
antibody (Ab-3 3B5) (catalog no. OP15L) was from Millipore. The monoclonal anti-
actin antibody (Ab-5) (catalog no. 612656) was from BD Bioscience. Horseradish 
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peroxidase-labeled goat anti-rabbit and anti-mouse IgG (H+L) (catalog nos. 111-035-
003 and 115-035-003, respectively) were purchased from Jackson ImmunoResearch 
Laboratories. Lapatinib (catalog no. L-4804) was obtained from LC Laboratories and 
recombinant human heregulin-β1 (HRG-β1; EGF-like domain, catalog no. 100–03) was 
obtained from Peprotech. 
 
2.4.2 Recombinant antibodies 
Clinical grade trastuzumab and pertuzumab were obtained from the UT 
Southwestern Pharmacy. For comparative purposes, trastuzumab and pertuzumab were 
also expressed in recombinant form using the same expression host as the other 
antibodies used in this study. Expression plasmids for the production of antibodies in 
stably transfected CHO cells were generated as follows: the genes encoding the heavy 
and light chain variable domains (VH and VL, respectively) of trastuzumab3, 
pertuzumab143, and Ab6 (US patent 20100266584A1; MM-12119) were synthesized 
commercially (Integrated DNA Technology, Genscript, or Thermo Fisher) and used to 
generate full-length human IgG1 and human kappa genes with the leader peptide 
(MGWSCIILFLVATATGVHS) from the anti-lysozyme antibody, Hulys10157, using 
standard methods of molecular biology. The vectors pcDNA 3.3 TOPO and 
pOptiVECTOPO (OptiCHO Ab Express Kit, Life Technologies, catalog nos. K8300–01 
and 12744017, respectively) were used for the expression of the light and heavy chain 
genes, respectively. To generate expression constructs for bispecific, tetravalent 
antibodies, a similar design to that described previously was used158. A linker sequence 
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containing a unique XhoI site was inserted at the 3′ end of the heavy chain genes 
(trastuzumab and pertuzumab) using a designed oligonucleotide and the PCR. A scFv 
gene encoding the Ab6 scFv with codons encoding a (Gly4Ser)3 linker peptide between 
the VH (JH) and VL gene was generated using standard methods of molecular biology. 
XhoI sites and Gly-Ser-Ser codons to connect the CH3 domain to the VH gene, were 
appended to the 5′ and 3′ ends of the scFv gene using the PCR. This scFv gene was 
cloned into the XhoI sites at the 3′ ends of the trastuzumab and pertuzumab heavy chain 
genes to generate full-length heavy chains linked to the Ab6 scFv. Complete sequences 
of all expression plasmids are available upon request. 
 
2.4.3 Transfection and expression of recombinant antibodies 
Light chain expression constructs were transfected into CD/DG44 CHO cells 
(Life Technologies, catalog no. A11000-01) using electroporation. Desired clones were 
selected in CD/DG44 CHO medium (Life Technologies, catalog no. 12610010) 
containing 500 µg/ml geneticin without the HT supplement. The clone expressing the 
highest levels of light chain was identified by screening culture supernatants with 
ELISAs using goat anti-human kappa light chain antibody for detection (Sigma-Aldrich, 
catalog no. A7164). Heavy chain expression constructs were then transfected into their 
respective stably transfected light chain expressing CD/DG44 CHO clones via 
electroporation and selected with Opti-CHO Medium (Life Technologies, catalog no. 
12681-011) containing 500 µg/ml geneticin. Supernatants of clones were screened by 
sandwich ELISA using goat anti-human IgG (Fab-specific, Sigma-Aldrich, catalog no. 
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I5260) as capture antibody and goat anti-human IgG (Fc-specific) conjugated to 
horseradish peroxidase (Sigma-Aldrich, catalog no. A0170) as detection antibody. The 
clones expressing the highest levels of antibody were expanded and cultured in 
increasing concentrations of methotrexate (MTX, 50 nM–4 µM), to induce gene 
amplification. Clones were further expanded in shake flasks (130 rpm) in 8% CO2 and 
antibody purified from culture supernatants using protein G-Sepharose (GE Healthcare, 
catalog no. 17-0618-05). Several antibodies were also scaled up and purified by 
BioXCell. 
 
2.4.4 Surface plasmon resonance analyses 
Surface plasmon resonance experiments were performed using a BIAcore 2000 
and previously described methods159, 160. Recombinant Fc-HER2 (R&D Systems, catalog 
no. 1129-ER-050) and HER3 (Acro Biosystems, catalog no. ER3-H5223) were coupled 
to flow cells of CM5 sensor chips to densities of 758 and 467 RU, respectively. 
Antibodies at a concentration of 50 nM were injected in phosphate buffered saline (PBS) 
plus 0.01% Tween at a flow rate of 10 µl/min. At the end of an 800 s dissociation phase, 
bound antibody was stripped from the flow cells using 0.1 M glycine, 0.9 M NaCl, pH 





The in vivo half-lives of 125I labeled Ab6tet and TAb6 were analyzed following 
intravenous or intraperitoneal delivery in BALB/c SCID mice (Jackson Laboratories) 
using previously described methods and whole body counting161. 
 
2.4.6 Proliferation assays 
Cells were plated in 96-well plates at a density of 2,500 cells per well and 
incubated overnight. Cells were treated with lapatinib (1 μM), HRG-β1 (6.25 nM), anti-
HER3 antibody Ab6 or the tetrameric form, Ab6tet, trastuzumab (anti-HER2), 
pertuzumab (anti-HER2), or the bispecific anti-HER2/ HER3 antibodies TAb6 and PAb6 
as indicated in the figure legends. Antibodies were used at a concentration of 50 nM 
unless otherwise indicated. Dimethyl sulfoxide or PBS were used as vehicle controls for 
lapatinib or HRG-β1/antibodies, respectively. After 5 d of incubation in a 37 °C 5% CO2 
incubator, cell proliferation was quantitated using CellTiter 96 AQueous One Solution 




Cells cultured to near confluence in 6-well plates were treated with lapatinib, 
HRG-β1 or antibodies as for proliferation assays. Following 15 min, 1 h, or 24 h 
incubation, cells were lysed using RIPA buffer (50 mM Tris, 150 mM NaCl, 0.5% 
sodium deoxycholate, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 2 µg/ml 
64 
 
aprotinin, 2 µg/ml leupeptin, 1 µg/ml pepstatin A, and 0.4 mg/ml pefabloc SC PLUS). 
Lysates were centrifuged for 20 min at 14,600 rpm at 4 °C and supernatants were 
collected. Protein concentrations in each lysate were determined using the BCA protein 
assay reagent (Pierce, catalog no. 23223). Total lysates were fractionated by SDS-PAGE 
and transferred onto polyvinylidene difluoride (PVDF) membranes (Millipore, catalog 
no. IPVH00010) or nitrocellulose membranes (Bio-Rad, catalog no. 162-0145). 
Membranes were incubated with 5% bovine serum albumin in Tris-buffered saline with 
0.1% Tween (TBST, pH 8.0) for 1 h following transfer to block non-specific binding 
sites. Blocked membranes were incubated with primary antibodies overnight at 4 °C 
with agitation. Prior to incubation with the secondary antibodies conjugated to 
horseradish peroxidase, blots were washed three times (10 min per wash) with TBST. 
Following incubation with secondary antibodies for 1 h and washing, bound secondary 
antibody was detected using chemiluminescent detection regent (GE Healthcare, catalog 
no. RPN 2209/AF). 
 
2.4.8 Fluorescence microscopy 
SK-BR-3 cells incubated overnight at a density of 50,000 cells per dish were 
treated with 50 nM Ab6, Ab6tet, or TAb6 for 5 or 15 min at 37 °C and then either 
immediately washed and fixed or chased in medium at 37 °C for 10, 20, or 45 min prior 
to washing and fixation. For fixation, cells were treated with 1.7% (w/v) 
paraformaldehyde for 10 min at 37 °C and then permeabilized with 0.05% (v/v) saponin 
for 10 min at room temperature in PBS. A pre-block with 4% BSA/PBS was performed 
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prior to staining with 2 µg/ml of polyclonal rabbit anti-LAMP-1 antibody (Abcam, 
catalog no. AB24170) and 12.5 µg/ml monoclonal mouse anti-EEA-1 (clone 14) from 
BD Bioscience (catalog no. 610456) for 30 min at room temperature. After blocking for 
30 min with goat serum (Sigma-Aldrich, catalog no. G6767), bound primary antibodies 
were detected by incubating cells with the following secondary antibody conjugates for 
25 min at room temperature: Alexa 555-labeled goat anti-human IgG (H+L) (Life 
Technologies, catalog no. A21433), Alexa 647-labeled goat anti-mouse IgG (H+L) (Life 
Technologies, catalog no. A21236) and Alexa 488-labeled goat anti-rabbit IgG (H+L) 
(Life Technologies, catalog no. A11034). Cells were washed twice with PBS between 
each incubation step and were stored at 4 °C in 1% BSA/PBS. Images were acquired 
using a Zeiss Axiovert 200M inverted fluorescence microscope with a 63X Plan 
Apochromat objective as described previously162, 163. Data was processed using custom 
written software in MatLab (MIAtool/LABSoft; 
http://www.wardoberlab.com/software/miatool/). 
 
2.4.9 Statistical analyses 
Statistical significance for differences in mean values of triplicate samples 
(immunoblots, ELISAs) was determined by Student t test. P values < 0.05 were 




2.4.10 Labeling of antibodies 
Antibodies were labeled with either Alexa Fluor® 647 carboxylic acid, 
succinimidyl ester (Life Technologies, Catalog # A-20173) or Alexa Fluor® 488 
carboxylic acid, succinimidyl ester (Life Technologies, Catalog # A-10235) using 
methods recommended by the manufacturer. Following the labeling reaction, antibodies 
were extensively dialyzed against PBS to remove unincorporated Alexa dye.  
 
2.4.11 Flow cytometry 
Cells were seeded at a density of 100,000 cells per well in 24 well plates, 
incubated overnight, and subsequently treated with either 1 µM lapatinib or vehicle 
control (DMSO) for 24 hours at 37 °C in a CO2 incubator. Treated cells were incubated 
with Alexa 647-labeled Ab6 and Alexa 488-labeled trastuzumab (50 nM each) for 15 
minutes at 37 °C in a CO2 incubator. Following incubation, cells were trypsinized, 
washed, and suspended in PBS. Stained cells were analyzed using a BD FACScalibur 
and data processed using FlowJo (Tree Star).  
 
2.4.12 Size exclusion chromatography 
Following protein G-Sepharose purification, antibodies were analyzed by size 
exclusion chromatography using HPLC and a Hiload 16/600 Superdex 200 pg column 
(GE Healthcare, catalog no. 28989335) or a Yarra 3U SEC-3000 (catalog no. 00H-4513-
E0) column. TAb6, Ab6tet and Ab6 were also purified as homodimeric, bispecific 
antibodies using the Hiload 16/600 Superdex 200 pg column. We observed that the 
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purified, homodimeric proteins had analogous activities to that of the material purified 
only on protein G-Sepharose in both MTS/proliferation and immunoblotting experiments 
(data not shown).  
 
2.4.13 Serum stability assays 
Antibodies were diluted into mouse serum (Thermo Scientific, catalog no. 
31881) to a concentration of 40 µg/ml and incubated for 3 or 6 days at 37 °C. Samples 
were diluted in PBS and analyzed by sandwich ELISA. 96 well plates were coated with 
goat species anti-human Cκ antibody (Sigma-Aldrich, catalog no. K3502), blocked with 
1% BSA/PBS and dilutions of serum samples in PBS added. Bound antibodies were 
detected using a goat anti-human IgG (Fc-specific) antibody conjugated to horseradish 





3. ENGINEERING ANTIBODY-RECEPTOR INTERACTIONS TO 
GENERATE HIGHER POTENCY ANTIBODY-DRUG CONJUGATES† 
 
3.1 Introduction 
Antibody-drug conjugates (ADCs) represent a rapidly expanding class of cancer 
therapeutics that combine the high specificity of antibodies with the potent cytotoxicity 
of drugs164-166. ADCs comprise antibodies that are chemically conjugated to highly 
cytotoxic drugs that include microtubule-disrupting agents (maytansinoids, auristatins) 
and DNA-damaging agents (calicheamicin, pyrrolobenzodiazepine dimers)164, 165. By 
targeting the drug to surface receptors on tumor cells, rather than systemic delivery of 
drug throughout the body, the toxicities associated with conventional chemotherapeutic 
treatments can be reduced. For the majority of current ADC formats, internalization and 
entry into acidic, degradative compartments are essential for drug delivery to the cytosol 
following binding of the ADC to target at the cell surface164, 165. Although the concept of 
targeting cancer with ADCs was originally proposed in the 1980s, until recently, clinical 
success was hampered by limitations in linkage chemistry for drug conjugation and 
insufficient potency of the drug164, 165, 167, 168. Major advances in linker technology 
combined with the identification of more potent drugs have led to the approval of several 
ADCs for use in the clinic and ~65 different ADCs in clinical trials164, 165, 169-171. 
However, despite the promise of ADCs in preclinical models, their translation into the 
                                                 
† This study has been submitted to the journal Nature Biotechnology (Kang JC, Sun W, 
Khare P, Karimi M, Wang X, Shen Y, Ober RJ, Ward ES) and is currently under review. 
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clinic has been hindered by dose-limiting toxicities, resulting in delivery of doses that 
can be suboptimal for therapeutic effects71, 172. 
To achieve the threshold payload of drug delivery to induce cell death of tumor 
cells using ADCs, relatively high levels of expression of the tumor target are 
necessary164, 165. For example, in clinical trials using the FDA-approved ADC 
comprising the HER2-specific antibody, trastuzumab, linked to the maytansinoid 
derivative, DM1 (trastuzumab-DM1, T-DM1169), breast cancer patients with lower levels 
of HER2 expression showed poor responses compared with those observed in patients 
with HER2-overexpressing tumors165, 173, 174. Although increased payload delivery could 
be achieved by delivering higher doses of ADC, this approach can lead to unacceptably 
high toxicities towards normal cells71, 172. Consequently, a major limitation of current 
ADC platforms is the observation of dose-limiting toxicities, that in some cases, 
necessitate the use of doses that are below those required for efficacy in preclinical 
models172. An additional issue with current targeting approaches is that ADC treatment 
can lead to resistance due to a reduction of the level of surface biomarker. For example, 
decreases in surface levels of targets such as HER2 have been observed in tumor cells 
following treatment with T-DM1175, 176. Such reductions in surface expression levels of 
the targeted cancer biomarker narrows the therapeutic window even further.  
A possible pathway towards overcoming these limitations is to develop ways of 
generating ADCs that deliver their payload more efficiently to the desired subcellular 
compartment, typically late endosomes or lysosomes, within target cells. Such an 
approach would endow the ADC with higher anti-tumor activity without the need to 
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increase the dose. Consideration of the trafficking and delivery pathway of an ADC and 
its target suggests a possible strategy. To release their toxic payload, the majority of 
current ADCs are designed to internalize and enter lysosomes164, 165. Due to the typically 
high affinity of the ADC for target at endosomal, acidic pH, payload delivery is 
therefore usually accompanied by target downregulation in these degradative 
compartments. These effects provide support for the premise that engineering the ADC 
to confer dissociation from its target within endosomes will enable payload entry into 
lysosomes, combined with recycling of unliganded target and reloading with additional 
ADC. This approach holds the promise to result in both increased payload delivery and 
reduced target downregulation, leading to therapeutic efficacy of ADCs at lower doses in 
combination with cytotoxicity towards cells with a broader range of target expression 
levels. A possible strategy towards achieving this is to generate ‘acid-switched’ ADCs 
comprising engineered antibodies that bind to their target with substantially higher 
affinity at near neutral, extracellular pH relative to acidic pH, to result in endosomal 
dissociation of the ADC following internalization into cells.  
In the current study we have used two distinct engineering approaches to 
generate acid-switched variants of the HER2-specific antibody pertuzumab177, 178. The 
acid-switched antibodies have been conjugated to monomethyl auristatin E (MMAE) to 
produce ADCs that, compared with their parent, wild type pertuzumab conjugates, 
deliver MMAE at higher levels to HER2-expressing cells and are more effective in 
reducing tumor growth in mouse xenograft models. Importantly, these enhanced 
therapeutic effects are observed for tumors that express intermediate levels of HER2. 
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Further, increased efficacy has been observed following the delivery of relatively low 
doses of acid-switched ADCs with only two drug molecules per antibody. Consequently, 
this approach has the potential to reduce the toxicities associated with current ADCs by 
increasing payload delivery within target cells. This novel platform technology for 






3.2.1 Generation of acid-switched antibodies 
We initially analyzed the interactions of two clinically-approved, HER2-specific 
antibodies (trastuzumab179 and pertuzumab177) with recombinant HER2-ECD 
(extracellular domain of HER2 fused to Fc) as the pH decreases from 7.4 to 6.0. The 
affinity of trastuzumab for HER2 is similar across the pH range 6.0-7.4, whereas the 
affinity of pertuzumab is around 10-fold higher at pH 7.4 compared with pH 6.0 (Fig. 3-
1). Pertuzumab was therefore chosen for further engineering to generate acid-switched 
variants180-182 using two approaches. First, we mutated complementarity-determining 
region (CDR) residues of pertuzumab that either directly interact with, or are in 
proximity to, HER2 residues in the X-ray crystallographic structure of the pertuzumab-
HER2 complex177 to histidine (Fig. 3-2a). Second, we randomly mutated residues in 
CDRH1, CDRH2, CDRH3 and CDRL2 (Fig. 3-2b), to generate five different phage 
display (scFv) libraries. Recombinant phage were panned against HER2-ECD with 





Figure 3-1. Surface plasmon resonance analyses of the interaction of clinical grade 
trastuzumab or clinical grade pertuzumab with immobilized recombinant human HER2 
extracellular domain fused to Fc (HER2-ECD). Antibodies were injected at either pH 7.4 
or pH 6.0 at concentrations ranging from 0.25-2,200 nM and equilibrium dissociation 
constants (KDs) determined. Representative traces for duplicate or triplicate injections 
for each analyte concentration are presented. Data shown are representative of at least 





Figure 3-2. Strategy for generating acid-switched variants of pertuzumab and 
equilibrium dissociation constants of pertuzumab (WT or mutant) interactions with 
HER2. The X-ray crystallographic structure of the pertuzumab:HER2 extracellular 
domain complex (Protein Data Bank: 1S78) is shown, with the pertuzumab VH domain,  
VL domain and HER2 domain II shown in cyan, light cyan and orange, respectively. 
Residues targeted for mutagenesis by histidine replacement (a) or for production of 
phage display libraries (b) are shown in green. (c) Residues Tyr55 (CDRL2) and Ser103 
(CDRH3) that were mutated to histidine to generate the YS mutant are shown in green. 
(d) Residues Ser55 (CDRH2) and Gly57 (CDRH2) that were mutated to His and Glu, 
respectively, to generate the SG mutant are displayed in green. (e) Equilibrium 
dissociation constants (KDs) for the interactions of HER2-ECD with WT pertuzumab or 
mutated variants, YS and SG. * estimated binding affinity from the amount bound at 
equilibrium (see methods). **N.D., not determined, since binding too low to estimate a 








Using histidine replacement of CDR residues, two mutated variants of 
pertuzumab (Tyr55 to His in CDRL2; Ser103 to His in CDRH3; Fig. 3-2c) with 
moderate increases in pH-dependence were identified by analyzing the binding of the 
corresponding recombinant, pertuzumab-derived Fab fragments to HER2-ECD at pH 7.4 
and 5.8. These two mutations were combined to generate the acid-switched variant ‘YS’ 
(Y55H-VL/S103H-VH) (Fig. 3-2c). In addition, an acid-switched variant with two 
mutations of centrally located residues in CDRH2, Ser55 to His, Gly57 to Glu (‘SG’) 
(Fig. 3-2d), was selected using phage display, and the pH-dependence of the 
corresponding phage for binding to HER2-ECD was substantially increased over that of 
phage bearing wild type (WT) pertuzumab (scFv; Fig. 3-3a). The equilibrium 
dissociation constants of the YS and SG variants, expressed as human IgG1/ 
antibodies, with HER2 were determined at different pH values (Fig. 3-2e). Binding of 
these two mutants at pH 6.5 and 7.0 was also analyzed (Fig. 3-2e), since the pH of the 
tumor microenvironment can be within this range due to lactate production by cancer 
cells183, 184. The YS and SG mutants have similar affinities for HER2 at pH 7.4, whereas 
the binding affinities of the SG mutant for HER2 decrease more rapidly than that of the 
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YS mutant as the pH is lowered (Fig. 3-2e). Both YS and SG mutants showed no 
detectable aggregation following storage at 4 °C or 37 °C (30 or 5 days, respectively), 
and were stable in human serum during a 5 day incubation period at 37 °C, indicating 





Figure 3-3. Binding behavior of phage bearing WT pertuzumab or SG mutant (as single 
chain Fvs, scFvs) and stability analyses of WT pertuzumab and SG, YS mutants (as full 
length human IgG1/antibodies). (a) Phage-displayed scFvs (WT or SG mutant) were 
analyzed for binding to HER2-ECD at pH 7.4 and 5.8 using ELISA. The ratio of signal 
measured at pH 7.4 to pH 5.8 was calculated. Data is representative of two individual 
experiments and the data show is the mean ratio (n = 6) ± SD. (b) WT pertuzumab or 
SG, YS mutants were stored at 4 °C for 0 days, 4 °C for 30 days, or 37 °C for 5 days and 
analyzed using size exclusion chromatography. (c) WT pertuzumab or SG, YS mutants 
were incubated in IgG-depleted, human serum for 0, 3, or 5 days at 37 °C. Antibodies 
were immunoprecipitated and analyzed by immunoblotting. Data shown are 









3.2.2 Acid-switched ADCs accumulate to higher levels within HER2-expressing cells 
We next conjugated WT pertuzumab, the YS and SG mutants to MMAE through 
hinge disulfide bonds to maleimidocaproyl-valine-citrulline-p-
aminobenzoyloxycarbonyl-monomethyl auristatin E (MC-VC-PAB-MMAE). The 
cysteines that form disulfide bonds in the hinge and between the upper hinge and C 
domain (Cys220, Cys229 of heavy chain; Cys214 of light chain; EU numbering185) were 
mutated to serines, to result in conjugation to Cys226 with a maximum drug:antibody 
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ratio (DAR) of two. This lower conjugation level was used to reduce the hydrophobicity 
that has been reported for ADCs with higher DARs and can lead to lower in vivo 
persistence186, 187. HPLC analyses using hydrophobic interaction and size exclusion 
columns indicated that the DAR ranges from 1.7-1.9, and that conjugation did not induce 
aggregation (Fig. 3-4a). The ADCs were stable in human serum for up to 5 days at 37 C 
(Fig. 3-4b), and analyses using ELISA demonstrated similar binding properties for 
HER2-ECD as their parent, unconjugated antibodies (Fig. 3-4c). 
 
 
Figure 3-4. Characterization of WT pertuzumab and acid-switched mutants (SG, YS) 
following conjugation to MMAE. (a) MMAE-conjugated antibodies (WT-MMAE, SG-
MMAE or YS-MMAE) were analyzed using a hydrophobic interaction column to 
determine the drug-to-antibody ratio (upper row). Analyses of MMAE-conjugated 
antibodies using size exclusion chromatography are also shown (lower row). (b) WT-
MMAE, SG-MMAE or YS-MMAE were incubated in IgG-depleted human serum for 0, 
3, or 5 days at 37 °C. Following incubation, ADCs were immunoprecipitated and 
analyzed by immunoblotting. (c) Antibodies (WT, SG and YS) and their respective 
MMAE-conjugated ADCs were analyzed for binding to HER2-ECD using ELISA at pH 
7.0 and 5.8. Mean values for triplicate samples ± SD are shown. For panels (b) and (c), 








We next investigated the effect of acid-switching on the accumulation of SG-
MMAE and YS-MMAE in the HER2-expressing tumor cell lines, SK-BR-3, HCC1954, 
SK-OV-3, MDA-MB-453 and JIMT-1. Analyses of surface HER2 expression levels for 
these cell lines confirmed earlier studies82, 188 demonstrating that SK-BR-3, HCC1954, 
and SK-OV-3 have high HER2 levels (HER2hi), whereas MDA-MB-453 and JIMT-1 
have intermediate levels (HER2int) (Fig. 3-5). To quantitate the intracellular 
accumulation and retention of the acid-switched pertuzumab-MMAE variants, the tumor 
cells were treated with Alexa 488-labeled ADCs for 0.5, 4, and 20 hours. Following 
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these incubation times, the surface signal was quenched using an Alexa 488-specific 
antibody188, 189 to quantitate internalized ADC (Fig. 3-6). Significantly higher 
intracellular levels of YS-MMAE and SG-MMAE were observed in all HER2hi and 
HER2int cells following incubation for 4 and 20 hours compared with WT pertuzumab 
conjugated to MMAE (WT-MMAE). These analyses also demonstrated that conjugated 
SG-MMAE accumulated to higher levels relative to YS-MMAE in the HER2-expressing 





Figure 3-5. Cell surface levels of HER2 on cancer cells. Cells were incubated on ice with 
33 nM Alexa 647-labeled pertuzumab (Pertuzumab), an Alexa 647-labeled isotype 
control (Control IgG), or media (Untreated) for 30 minutes, washed and analyzed by 




Figure 3-6. Acid-switching results in increased accumulation of ADCs in HER2-
expressing tumor cells. Cells were incubated in triplicates with 10 nM Alexa 488-labeled 
MMAE-conjugated antibody (WT, SG, YS or control hen egg lysozyme-specific 
antibody, C) for the indicated times at 37 °C, washed, incubated with Alexa 488-specific 
quenching antibody and analyzed by flow cytometry. Mean fluorescence intensities 
(means of triplicate samples) showing levels of cell-associated Alexa 488-labeled ADCs 
at the indicated times. Error bars indicate SD. Statistically significant differences are 





Fluorescence microscopy was used to investigate the intracellular location of the 
acid-switched ADCs. Cells were pulse-chased with fluorescently labeled dextran to label 
lysosomes163, and subsequently treated with ADCs for 4 or 20 hours (Fig. 3-7). 
Consistent with the flow cytometry analyses, both SG-MMAE and YS-MMAE 
accumulated to higher levels than WT-MMAE in dextran-positive lysosomes within 





Figure 3-7. Acid-switching results in increased delivery of ADCs to dextran-positive 
lysosomes. MDA-MB-453 cells were incubated with 5 µM Alexa 647-labeled dextran 
for 2 hours followed by a 3 hour chase period to label lysosomes. Following dextran 
treatment, cells were incubated with 10 nM Alexa 488-labeled/MMAE-conjugated 
antibodies (WT, SG or YS) for 4 hours (a) or 20 hours (b). Following washing, cells 
were treated with Alexa 488-specific antibody for 30 minutes on ice to quench cell 
surface-associated signal. Samples were then fixed and imaged. Cropped regions are 
expanded in the lower left region of each image. Alexa 488 and Alexa 647 are 
pseudocolored red and green, respectively, in the overlays. Size bars = 5 µm (larger 






3.2.3 Acid-switched ADCs are more effective in reducing the growth of tumor cells 
We next evaluated the ability of the acid-switched ADCs to reduce tumor cell 
viability. HER2-expressing cell lines were treated with ADCs and cell viability 
determined following 4 days incubation. Consistenst with the increases in accumulation 
of the acid-switched ADCs in HER2int cells, these ADCs were more effective than WT-
MMAE in reducing cell viability (Fig. 3-8a). By contrast, with the exception of SKOV-3 
cells, SG-MMAE, YS-MMAE, and WT-MMAE showed similar dose responses for 
cytotoxicity towards the HER2hi cell lines, SKBR-3 and HCC1954. As expected, in 
MDA-MB-468 cells that are HER2neg 82, high ADC doses were necessary to induce an 
inhibitory effect, and there was no difference between WT-MMAE, SG-MMAE and YS-
MMAE. Collectively, our observations indicate that acid-switched ADCs are more 
effective than their WT parent antibody-derived ADCs in targeting HER2-expressing 





Figure 3-8. Acid-switched ADCs are more effective at reducing proliferation of HER2-
expressing cells and deliver higher levels of MMAE to cells compared with WT-
MMAE. (a) HER2-expressing cancer cells, or HER2-negative (MDA-MB-468) cells, 
were treated with the indicated concentrations of MMAE-conjugated antibodies (WT, 
SG, YS or control hen egg lysozyme-specific antibody, C) for 4 days and cell viability 
determined using the MTS reagent. (b) MDA-MB-453 and JIMT-1 cancer cells were 
incubated with 10 nM MMAE-conjugated antibodies (WT, SG or YS) for 20 hours. 
Samples were subsequently lysed in methanol and cell-associated MMAE quantitated 
using LC-MS/MS. Means of triplicate samples are shown, and error bars indicate SD. 
Statistically significant differences between YS or SG and WT are indicated by * (n = 3 
independent samples per group; one-way ANOVA and Tukey’s multiple comparison 




We also used LC-MS/MS to quantitate the levels of MMAE in the HER2-
expressing cell lines, MDA-MB-453 and JIMT-1, following treatment for 20 hours with 
10 nM WT-MMAE, SG-MMAE or YS-MMAE (Fig. 3-8b). These analyses 
demonstrated that significantly higher levels of MMAE were present in these cells 
following treatment with SG-MMAE or YS-MMAE compared with WT-MMAE, 
although the difference was greater for MDA-MB-453 cells (~3-fold difference vs. ~1.5-
fold for JIMT-1) (Fig. 3-8a). Consequently, the increased cytotoxicity of the acid-
switched ADCs are consistent with their higher activity in delivering MMAE to target 
cells. 
 
3.2.4 Acid-switching enhances therapeutic effects in mouse xenograft models 
Prior to analyzing the therapeutic effects of the acid-switched ADCs, we 
investigated their pharmacokinetic behavior in BALB/c SCID mice. WT-MMAE, SG-
MMAE and YS-MMAE have similar -phase half-lives of 190.6 ± 4.4 hours, 184.4 ± 
11.7 hours, and 195.2 ± 29.5 hours, respectively (mean ± SD, n = 5 mice/group; Fig. 3-
9). The therapeutic effects of the acid-switched ADCs were next compared with WT-
MMAE and the clinically approved ADC, trastuzumab-DM1 (T-DM1), in mouse 
xenograft models. A dose (2 mg/kg) that is suboptimal for T-DM182 was used to 
evaluate whether the acid-switched ADCs had greater anti-tumor effects. Female 
BALB/c SCID mice were implanted with MDA-MB-453 (HER2int) cells and treated 
with ADC twice, with a three week interval (Fig. 3-10a). Treatment with SG-MMAE or 
YS-MMAE is more effective than WT-MMAE, T-DM1 or WT pertuzumab 
86 
 
(unconjugated) in inhibiting tumor growth (Fig. 3-10a). For three mice in the SG-
MMAE treatment group (n = 8), tumors could not be detected at the end of the 
experiment (Fig. 3-11a). We also treated mice bearing JIMT-1 (HER2int) tumors, that are 
relatively resistant to T-DM182, 190, with 2 mg/kg SG-MMAE, WT-MMAE, T-DM1 and, 
as controls, unconjugated WT pertuzumab or SG mutant at weekly intervals for three 
weeks (Fig. 3-10b). The therapeutic effect of SG-MMAE was significantly higher than 
that of WT-MMAE, T-DM1, and unconjugated control antibodies (Fig. 3-10b,3-11b). In 
all therapy experiments, ADC delivery did not result in elevated alanine 
aminotransferase (ALT) activity or significant weight loss, indicating that the ADCs are 





Figure 3-9. Pharmacokinetic behavior of WT-MMAE and acid-switched ADCs, SG-
MMAE and YS-MMAE. Female BALB/c SCID mice (n = 5 mice/group) were injected 
intravenously with 125I-labeled ADC and radioactivity levels in the whole body (a) or 
blood (b) were determined at the indicated times. Data shown represent means of 





Figure 3-10. Acid-switched ADCs have higher therapeutic efficacy against tumor 
xenografts than WT-MMAE or T-DM1. (a) Female BALB/c SCID mice bearing 
HER2int, MDA-MB-453 tumors were treated twice, with a 21 day interval, with 2 mg/kg 
ADC (WT-MMAE, SG-MMAE or YS-MMAE), T-DM1, unconjugated WT pertuzumab 
(WT) or vehicle (PBS) (n = 7-8 mice per group). Tumors were measured every 3-4 days. 
(b) Female BALB/c SCID mice bearing HER2int, JIMT-1 tumors were treated weekly 
(four times) with 2 mg/kg ADC (WT-MMAE or SG-MMAE), T-DM1, unconjugated 
WT or SG mutant, or vehicle (PBS) (n = 6-7 mice per group). Measurements shown 
indicate mean tumor volume for mice within each treatment group. For (a) and (b), 
arrowheads and error bars indicate treatment day and SE, respectively. Statistically 
significant differences at the experimental endpoints in (a) and (b) are indicated by * 
(two-tailed Mann-Whitney U test and unpaired two-tailed t-test, respectively; p < 0.05). 





Figure 3-11. Analyses of excised tumors, serum alanine transaminase (ALT) activity, 
and body weight of female BALB/c SCID mice following treatment with ADCs. (a) 
Female BALB/c SCID mice bearing MDA-MB-453 tumors were treated twice, with a 21 
day interval, with 2 mg/kg ADC (WT-MMAE, SG-MMAE or YS-MMAE), T-DM1, 
unconjugated WT pertuzumab (WT) or PBS (n = 7-8 mice per group). (b) JIMT-1 
xenografts were treated weekly (four times) with 2 mg/kg ADC (WT-MMAE or SG-
MMAE), T-DM1, WT or SG mutant, or PBS (n = 6-7 mice per group). Tumors from (a) 
and (b) were extracted and photographed at the end of the experiment. Note that tumors 
could not be detected in 3 of 8 mice treated with SG-MMAE, and 5 tumors are therefore 
shown in (a). (c) Blood was collected from mice 4-5 days after the second (MDA-MB-
453 xenograft model, n = 7-8 mice/group) or fourth (JIMT-1 xenograft model, n = 6-7 
mice/group) dose of ADCs or control and tested for ALT activity, where the units of mU 
are defined as nmol/min. The mean ALT activity ± SE for each group is presented. No 
statistical significance (n.s.) was found (one-way ANOVA with Tukey’s multiple 
comparisons test; p > 0.05). (d) Body weights of BALB/c SCID mice treated as in panel 
(c) were determined at the indicated times. Arrowheads indicate treatment days, and 
mean weight ± SE for each group is shown. The data shown corresponds to the mice 
used in the treatment experiments presented in Fig. 5. Data is representative of two 










3.2.5 Molecular modeling analyses of the interaction of the SG mutant with HER2 
We carried out modeling studies to investigate the molecular basis of the loss of 
affinity at pH 5.8 of the lead acid-switched variant, SG, for HER2 relative to WT 
pertuzumab (Fig. 3-12). These analyses resulted in a model in which protonation of 
His55 in CDRH2, that replaces Ser55 in WT pertuzumab, at N of the imidazole ring 
predominates over that of N1 at near neutral pH, whereas the protonated N1 tautomer 
is favored at lower, acidic pH (5.8). Protonation of N1 leads to an electrostatic 
interaction with Glu57 (E57) in CDRH2 of SG in combination with interactions with 
Tyr252 of HER2. By contrast with the solvent exposure of Glu57 and Tyr252 residues in 
the SG mutant:HER2 complex at pH 7.4, the change in protonation state of histidine at 
pH 5.8 results in reorientation of Glu57 and Tyr252. In the model, this reorientation 
results in an unfavorable desolvation penalty that is a primary contributor to the loss of 





Figure 3-12. Structural modeling comparing the interaction of WT pertuzumab with the 
acid-switched mutant, SG, to HER2 at pH 7.4 and 5.8. (a) Analyses of the contribution 
of van der Waals (vdW), geometry (Geo), nonpolar hydration free energy (based on the 
solvent-accessible surface area, or SASA), and continuum electrostatics (Elec) to the 
differences in binding free energies (G) between the SG mutant and WT pertuzumab 
interacting with HER2 at pH 7.4 and 5.8. (b) Energy decompositions of the Elec 
interactions shown in (a) for the residues that make the largest energetic contributions to 
the different binding behavior of WT and SG (HER2 and pertuzumab CDRH2 residues 
are shown in orange and cyan, respectively), with the most important contributors 
indicated by boxes. (c,d) The differences in the protonation states (residue His55 and 
Ser55 of SG and WT, respectively) and conformational states (residue Tyr252 of HER2) 
between WT pertuzumab and the SG mutant at pH 7.4 and 5.8. The modeled structures 
of the pertuzumab:HER2 extracellular domain complex are shown, with the pertuzumab 
VH domain, VL domain and HER2 domain II shown in cyan, light cyan, and orange, 









Despite their promise as therapeutic agents, the clinical use of ADCs can 
frequently provoke adverse events, leading to the delivery of doses that are suboptimal 
for tumor destruction172. To overcome these limitations, in the current study we describe 
a novel ADC platform that results in higher efficiency of cytotoxic drug delivery to 
target cells. Specifically, we have generated acid-switched ADCs specific for the tumor 
target, HER2, that have been engineered to bind with substantially higher affinity to this 
receptor at near neutral, extracellular pH, than at acidic, endosomal pH. We demonstrate 
that, relative to an ADC comprising the parent wild type antibody, pertuzumab, acid-
switched ADCs deliver the cytotoxic drug, MMAE, more efficiently to tumor cells and 
have more potent therapeutic effects in mouse xenograft models. As such, this approach 
has broad implications for the engineering of ADCs with the goal of achieving 
therapeutic efficacy with lower doses. 
To date, the targeting of HER2 with ADCs such as T-DM1 has met with 
disappointing results for HER2-positive tumors that do not overexpress this receptor165, 
173, 174. Our demonstration that HER2int cells can be effectively targeted with acid-
switched ADCs suggests that tumors with lower target expression levels, that lead to 
narrow therapeutic windows with conventional ADCs, could be successfully treated with 
engineered ADCs of this class. By contrast with the improved activity of acid-switched 
ADCs against HER2int tumor cells, however, we do not see significant differences for 
the HER2-overexpressing cells, SK-BR-3 and HCC1954. A possible reason for these 
observations is that for cytotoxicity, internalization of a relatively low proportion of 
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surface HER2 molecules is necessary on HER2-overexpressing cells, resulting in less 
dependence on endosomal HER2:ADC dissociation and ADC reloading compared with 
HER2int cells. It is also conceivable that acid-switching could be combined with 
strategies to enhance ADC internalization, such as the co-opting of HER2 into higher 
order aggregates with antibody mixtures82, 191, biparatopic antibodies82, or into cross-
linked complexes with the internalizing receptor, CD63, using bispecific antibodies192, to 
further improve therapeutic efficacy. 
The engineering of antibodies to generate acid-switched variants has been 
described as a strategy to enhance the clearance of soluble target antigens180-182, 193, 194. 
Based on these studies, the relatively high affinity of (wild type) pertuzumab for HER2 
at endosomal pH would be expected to limit endosomal dissociation, consistent with the 
current study. Nevertheless, the intrinsic pH-dependence with ~10 fold higher affinity 
binding at pH 7.4 relative to pH 6.0, suggested that this antibody is a suitable candidate 
for further engineering to generate acid-switched variants with negligible binding at 
acidic, endosomal pH. Combined with the use of the X-ray crystallographic structure of 
the pertuzumab:HER2 complex177 as a guide, we have generated acid-switched variants 
of pertuzumab using two approaches: first, we have substituted ‘likely’ candidate 
residues in the CDRs with histidine. This approach resulted in two mutated variants 
(Y55H in CDRL2, S103H in CDRH3) with increased pH-dependence that were 
subsequently combined to generate the YS mutant. Second, CDR residues proximal to 
the interaction site were randomly mutated and pH-dependent variants selected using 
phage display to isolate the SG mutant. Modeling has been used to investigate the 
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molecular basis for the increased pH-dependence of the lead SG mutant, and indicates 
that pH-dependent changes in the protonation of the imidazole side chain of His55, that 
replaces Ser55 in WT pertuzumab, results in a relatively large desolvation penalty for 
proximal HER2 residues at lower, acidic pH. 
Although the expression of the IgG-recycling receptor, FcRn, would be expected 
to mitigate the effect of endosomal dissociation of acid-switched ADCs from their 
target195, this receptor is expressed at low to undetectable levels in the majority of breast, 
prostate and lung tumor cells196, 197. This low expression enables the accumulation of 
increased levels of albumin, a second ligand for FcRn198, within the cells due to reduced 
recycling following fluid phase internalization. Following lysosomal delivery of 
albumin, its degradation to amino acids represents an important supply of nutrients to 
meet the extraordinarily high metabolic needs of cancer cells196, 199, 200. Consequently, 
we expect that for many tumor types, acid-switched ADCs will not be efficiently 
recycled following endosomal dissociation, by contrast with FcRn-mediated recycling in 
normal cells, the majority of which express this receptor201, 202. 
In summary, we have described a novel ADC platform that, based on improved 
intracellular trafficking, results in increased delivery of cytotoxic payload to target cells. 
We show that acid-switched ADCs have higher therapeutic efficacy in HER2int tumor 
cells compared with ADCs containing the parent, WT antibody or T-DM1. This 
approach not only has potential to treat patients with tumors expressing a broad range of 
HER2 levels, but also promises to have general applicability in overcoming the current 
limitations of dose-limiting toxicities for other tumor targets.  
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3.4 Materials and methods 
3.4.1 Cell lines and reagents 
The following cancer cell lines were obtained from the American Type Culture 
Collection (Manassas, VA, USA): SK-BR-3, SK-OV-3, MDA-MB-453, and MDA-MB-
468. SK-BR-3 and SK-OV-3 cells were cultured in McCoy’s 5a medium, whereas 
MDA-MB-453 and MDA-MB-468 cells were cultured in RPMI1640 medium. The 
breast cancer cell line JIMT-1 was obtained from AddexBio and cultured in DMEM 
medium. The HCC1954 cell line was a generous gift from Drs. Adi Gazdar, John Minna, 
and Kenneth Huffman (Hamon Center for Therapeutic Oncology Research, University 
of Texas Southwestern Medical Center at Dallas) and was cultured in RPMI1640 
medium. All media were supplemented with 1% penicillin/streptomycin, 1% GlutaMAX 
(Thermo Fisher Scientific, Waltham, MA, USA), 1% sodium pyruvate and 10% fetal 
calf serum. The cell lines were tested monthly for mycoplasma contamination and were 
authenticated annually at the University of Arizona Genetics Core through DNA 
fingerprint analysis.  
 
3.4.2 Histidine scanning of pertuzumab 
The sequences encoding the pertuzumab variable heavy (VH) and variable light 
(VL) chain domains177 were synthesized by GenScript (Piscataway, NJ, USA) and used 
to generate an expression vector to produce pertuzumab Fab fragments (human CH1, 
C) using standard methods of molecular biology. Residues in the complementarity-
determining regions (CDRs) of the VH and VL domain genes of pertuzumab were 
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selected for histidine scanning using the crystal structure of pertuzumab in complex with 
HER2 (Protein Data Bank accession code 1N8Z)177 in PyMOL (Schrödinger, New York, 
NY, USA) as a guide. The following residues, that are in proximity to or contact HER2, 
were targeted: Asp31, Tyr32, Asn54, Tyr60, Leu100, Gly101, Pro102, Ser103, Tyr105, 
Asp107 in the VH domain and Tyr55 in the VL domain. These residues were mutated to 
histidine using splicing by overlap extension203, and the corresponding Fab fragments 
were expressed as periplasmically secreted proteins using E. coli as an expression 
host204. Fab fragments were purified using Ni2+-NTA-agarose204. 
 
3.4.3 Generation of phage display libraries 
To express pertuzumab as a single chain Fv fragment (scFv) using the phagemid, 
pHEN1205, the expression vector for the pertuzumab Fab fragment was modified using 
standard methods of molecular biology to insert a linker peptide [(Gly4Ser)3 linker] 
between the pertuzumab VH and VL domain genes, followed by cloning into pHEN1 as 
a NotI-SfiI fragment. Libraries were generated with random mutations in CDR1, 2 and 3 
of the VH domain (targeting Asp31, Tyr32 and Thr33; Asn75, Ser76, Gly77 and Gly78; 
Gly101, Ser103, Tyr105 and Tyr108) and CDR2 of the VL domain (targeting Ile48, 
Tyr49 and Ser50 or Ala51, Tyr53, and Tyr55). The following oligonucleotides were 
used, combined with splicing by overlap extension, to generate five libraries: Library 1: 
CDRH1Back, 5’ GCT TCT GGA TTC ACA TTC ACA NNB NNB NNB ATG GAT 
TGG GTG AGA CAG GCT 3’ and CDRH1For, 5’ TGT GAA TGT GAA TCC AGA 
AG C 3’; Library 2: CDRH2Back, 5’ TGG GTG GCT GAT GTG AAT CCT NNB NNB 
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NNB NNB TCT ATC TAC AAT CAG AGA TTC 3’ and CDRH2For, 5’ AGG ATT 
CAC ATC AGC CAC CCA 3’; Library 3: CDRH3Back, 5’ TAC TAC TGT GCT AGA 
AAT CTG NNB CCT NNB TTC NNB TTC GAT NNB TGG GGA CAG GGA ACA 
CTG 3’ and CDRH3For, 5’ CAG ATT TCT AGC ACA GTA GTA 3’; Library 4: 
CDRL2-1Back, 5’ CCT AAG CTG CTG ATC TAC TCT NNB TCT NNB AGA NNB 
ACA GGA GTG CCT TCT AGA 3’ and CDRL2-1For, 5’ AGA GTA GAT CAG CAG 
CTT AGG 3’; Library 5: CDRL2-2Back, 5’ GGA AAG GCT CCT AAG CTG CTG 
NNB NNB NNB GCT TCT TAC AGA TAC ACA GGA 3’ and CDRL2-2For5, 5’ CAG 
CAG CTT AGG AGC CTT TCC 3’ (N = A, C, T or G; B =  C, T, or G. The resulting 
gene libraries were transfected into E. coli TG1 (Lucigen, Middleton, WI, USA) to 
generate libraries of 2.6 x106-1.7 x 108 clones. Each library was pooled and grown 
overnight at 30 °C in 4XTY broth supplemented with M13KO7 helper phage (New 
England Biolabs, Ipswich, MA, USA), 100 µg/ml ampicillin, and 50 µg/ml kanamycin. 
Phage were precipitated with a solution of PEG-8000 and NaCl to a concentration of 4% 
PEG-8000/0.5 M NaCl followed by centrifugation at 10,000 RCF. The phage were 
washed with 4% (w/v) PEG-8000/0.5 M NaCl prior to suspension in 1% (w/v) bovine 
serum albumin (BSA)/phosphate buffered saline (PBS). To select phage that display 
pertuzumab-derived scFvs that bind to HER2 with increased pH-dependence, 
recombinant phage were first pre-panned in Nunc 96-well flat-bottom immuno plates 
(Thermo Fisher Scientific) coated with 4% (w/v) milk powder/PBS (pH 7.4), and 
subsequently transferred to 96-well Nunc plates that had been coated with 2 µg/ml 
recombinant HER2-ECD (R&D Research, Minneapolis, MN, USA) and blocked with 
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4% (w/v) milk powder/PBS (pH 7.4). Following a 2 hour incubation, the plates were 
washed 5 times with PBS plus 0.1% Tween 20 (PBST) pH 7.4 followed by 5 washes 
with PBS pH 7.4. Bound phage were then eluted by the addition of 20 mM 2-(N-
morpholino)ethanesulfonic acid (MES) pH 5.8 for 10 minutes. The eluted phage were 
amplified by re-infection of E. coli TG1, followed by two additional rounds of selection 
using 10 washes with PBST pH 7.4 and 10 washes with PBS pH 7.4. Eluted phage (pH 
5.8) from the third round of panning were used to re-infect E. coli TG1, single clones 
expanded in 96 deep well plates and treated with helper phage using previously 
described methods206. Culture supernatants containing phage were used in ELISAs with 
plates coated with recombinant HER2-ECD, followed by washing with PBST pH 7.3 or 
pH 5.8. Bound phage were detected using anti-M13 antibody conjugated to horse radish 
peroxidase (HRP) (GE Healthcare, Chicago, IL, USA) at a 1:5,000 dilution in 4% milk 
powder in PBS, pH 7.3 or 5.8, followed by detection with 3’3’5,5’ tetramethylbenzidine 
substrate. For ELISAs using purified phage, phage suspensions were added to each well 
and binding at pH 5.8 and 7.4 was detected using the same protocol. 
 
3.4.4 Recombinant antibodies 
VH and VL domain genes encoding acid-switched pertuzumab variants that were 
obtained by histidine scanning or phage display were used to generate constructs for the 
expression of full length human IgG1, Cκ antibodies using standard methods of 
molecular biology and the vector, pcDNA3.4 (Life Technologies). The hinge disulfide 
bonds that link the Cκ domain to the hinge region and one hinge disulfide that links the 
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two heavy chains to each another were removed by mutating the light chain cysteine 
(Cys214; EU numbering185) and two heavy chain cysteines (Cys220, Cys229; EU 
numbering185) to serine. 
For use as a control antibody, the VH and VL domains of the hen-egg lysozyme 
antibody, HuLys10207, were reformatted as heavy and light chain constructs to generate a 
full length human IgG1/ antibody with one hinge disulfide (as above) using pcDNA3.4.  
Recombinant antibodies were produced in Expi293F cells (Life Technology, 
Carlsbad, CA, USA) following transient transfection with the Expi293 expression 
system kit (Life Technology) as previously described208. Antibodies were purified from 
culture supernatants using protein G-Sepharose (GE Healthcare) and dialyzed against 
PBS. Purified antibodies were loaded onto a Hiload 16/600 Superdex 200 gel filtration 
column (GE Healthcare) to remove aggregates, followed by analyses of the ‘monomeric’ 
antibodies using a Yarra 3000 column (Phenomenex, Torrance, CA, USA).  
Clinical grade trastuzumab and pertuzumab were acquired from the University of 
Texas Southwestern Medical Center Pharmacy. 
 
3.4.5 Surface plasmon resonance analyses 
Binding analyses were carried out using a Biacore 2000 or T200 (GE 
Healthcare). Flow cells of CM5 sensor chips were coupled using amine coupling 
chemistry with recombinant HER2-ECD (R&D Research) or coupling buffer only (10 
mM sodium acetate pH 4.8) as a reference. Fab fragments or antibodies were injected 
over immobilized HER2-ECD (coupled to densities ranging from 426-956 relative units 
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on flow cells of CM5 sensor chips) at a flow rate of 5 or 10 µl/min at 25 °C in PBS plus 
0.01% (v/v) Tween and 0.05% (w/v) sodium azide (pH 7.4, 7.0, 6.5, 5.8). Flow cells 
were regenerated following each injection using 0.15 M NaCl/0.1 M glycine (pH 2.8) 
buffer. For full length antibodies, equilibrium dissociation constants were determined 
using custom written software209 to yield apparent dissociation constants (due to bivalent 
binding of the antibodies to immobilized HER2). The KD of the YS mutant at pH 5.8 
was too high to accurately determine (i.e. levels of binding close to saturation could not 




, where KD is the calculated equilibrium dissociation constant (nM), CK is the 
concentration of analyte flowed over the chip (nM), Rmax is the maximum analyte 
binding capacity (RU), and Req(Ck) is the equilibrium signal for concentration CK 
(RU)209.  
 
3.4.6 Conjugation and labeling of antibodies 
Antibodies (10 µM) in PBS were reduced by addition of 80 µM of tris(2-
carboxyethyl)phosphine (TCEP) and 1 mM ethylenediaminetetraacetic acid (EDTA) for 
2 hours at 37 °C. Reduced antibodies were cooled on ice and 40 µM maleimidocaproyl-
valine-citrulline-p-aminobenzoylcarbonyl-monomethyl auristatin E (MMAE; Concortis, 
San Diego, CA, USA) was added. Following 4 hours incubation on ice, unconjugated 
MMAE was removed by extensive dialysis against PBS. Conjugated antibodies were 
analyzed using size exclusion chromatography (Yarra 3000) and hydrophobic interaction 
chromatography (HIC; TSKgel Butyl-NPR; Tosoh, Tokyo, Japan) to determine drug-to-
102 
 
antibody ratios (DARs). For HIC, solvent A was 10 mM potassium phosphate with 1.5 
M ammonium sulfate at pH 7.0 and solvent B was 10 mM potassium phosphate at pH 
7.0 with 20% (v/v) isopropanol. The gradient method used was 0-5 min (0% B), 5-15 
min (0% to 100% B), and 15-20 min (100% B) at a flow rate of 0.5 ml/min.  
ADCs were labeled with Alexa 488 Fluor (Thermo Fisher Scientific) or 
radiolabeled with 125I-Iodogen [Perkin Elmer or MP Biomedical (Solon, OH, USA)] as 
described previously210, 211, except that a 1:1 molar ratio of Alexa 488:ADC was used 
during the labeling reaction. 
 
3.4.7 Enzyme-linked immunosorbent assays 
ADCs and antibodies were analyzed by ELISA for their binding to HER2-ECD 
(R&D Research). 96-well Nunc plates were coated with HER2-ECD at a concentration 
of 2 µg/ml overnight at 4 °C. ADCs and antibodies were diluted in 4% (w/v) milk 
powder/PBS (pH 5.8 or pH 7.0) and added to coated plates at concentrations ranging 
from 0.1 nM to 200 nM. Plate wells were washed 4 times with PBST (pH 5.8 or 7.0, as 
indicated). Antibodies and ADCs were detected with goat anti-human IgG (Fab-specific) 
conjugated with HRP (Sigma-Aldrich). 
 
3.4.8 Serum stability analyses of antibodies and ADCs 
Human serum (Sigma-Aldrich, St. Louis, MO, USA) was depleted of 
endogenous IgG by passage through a protein G-Sepharose column. Antibodies and 
ADCs were incubated at 40 µg/ml in IgG-depleted serum for 0, 3, or 5 days at 37 °C 
followed by immunoprecipitation using agarose beads coupled to goat anti-human Fc-
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specific antibody (Sigma-Aldrich). Immunoprecipitated antibodies and ADCs were run 
on SDS-polyacrylamide gels and transferred onto nitrocellulose membranes (0.45 µm 
pore size; Genesee Scientific, San Diego, CA, USA). Immunoblotting was carried out 
using standard methods with goat anti-human IgG (H + L) antibodies conjugated with 
HRP (Jackson Immunoresearch, West Grove, PA, USA). HRP was detected using 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) followed 
by scanning with a C-DiGit blot scanner (LI-COR Biosciences, Lincoln, NE, USA).  
 
3.4.9 ADC accumulation assay 
Cancer cells were plated in 48-well plates and incubated overnight in a 37 °C 
incubator with 5% CO2, followed by treatment with 10 nM Alexa 488-labeled ADC in 
medium (pH 7.0) for 0.5, 4, and 20 hours. Treated cells were cooled on ice and surface 
fluorescence of Alexa 488-labeled ADC quenched with 5 µg/ml rabbit anti-Alexa 488 
antibody (Thermo Fisher Scientific) for 30 minutes at 4 °C. The quenching efficiency 
was determined using separate cell samples which had been incubated with Alexa 488-
labeled ADC on ice (to prevent internalization) followed by treatment with anti-Alexa 
488 antibody or vehicle control. Samples were washed, harvested by trypsinization, 
resuspended in PBS, analyzed using a BD Accuri C6 flow cytometer (BD Biosciences, 
San Jose, CA, USA) and data processed with FlowJo (FlowJo, Ashland, OR, USA). 
 
3.4.10 Fluorescence microscopy 
MDA-MB-453 cells were plated in coverglass-bottomed Mattek dishes and 
allowed to adhere overnight in a 37 °C, 5% CO2 incubator. Cells were pre-treated with 
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Alexa 647-labeled dextran (5 µM pulse for 2 hours and chase for 3 hours) followed by a 
treatment of 10 nM Alexa 488-labeled WT-MMAE, SG-MMAE, or YS-MMAE for 4 or 
20 hours. Samples were treated with 5 µg/ml rabbit anti-Alexa 488 antibody for 30 
minutes on ice to quench surface Alexa 488 fluorescence, and subsequently fixed at 
room temperature with 3.4% (w/v) paraformaldehyde plus 0.025% (v/v) glutaraldehyde. 
Fixed cell samples were imaged with an Axio Observer Z1 inverted epifluorescent 
microscope (Zeiss, Oberkochen, Germany) equipped with a 63 X, 1.4 NA Plan-
Apochromat objective (Zeiss), and a Zeiss 1.6 X internal optovar. A broadband LED 
lamp (X-cite 110LED, Excelitas Technologies, Waltham, MA, USA) was employed as 
the excitation source, and a digital CCD camera (Hamamatsu Orca-ER; Hamamatsu 
Photonics, Japan) as the detector. Standard fluorescent filter sets for Alexa 488 (FITC-
3540C) and Alexa 647 (Cy5-4040C) were purchased from Semrock (Rochester, NY, 
USA). Images were acquired at room temperature using custom software written in Java 
and the C programming language. Acquired images were analyzed using the custom 
written software MIATool212. Acquired images for Alexa 488 were linearly adjusted 
with the same intensity adjustment settings. Independent linear adjustments were made 
for the Alexa 647 signal for each time point. 
 
3.4.11 Cell viability assays 
Cells were plated in 96-well plates at a density of 5,000 cells per well and treated 
with different concentrations of ADCs. Cells were treated for 4 days in a 37 °C, 5% CO2 
incubator, followed by the use of CellTiter 96 AQueous One Solution Proliferation 
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Assay kit (Promega, Madison, WI, USA) to determine cell viability using the 
manufacturer’s protocol.  
 
3.4.12 Quantitation of MMAE using LC-MS/MS 
Cancer cells were plated in 6 well plates and incubated overnight in a 37 °C, 5% 
CO2 incubator. Cells were treated with 10 nM ADC for 20 hours, followed by washing 
with PBS and harvesting by trypsinization. Trypsinized cells were counted and 
resuspended in 100% methanol containing 1.67 ng/ml deuterium-labeled MMAE (D8-
MMAE; MedchemExpress, Monmouth Junction, NJ, USA) at a density of 8.3 x 105 cells 
per ml. Samples were lysed for 16 hours at -20 °C and then centrifuged at 21,100 RCF 
for 15 mins at 4 °C. The supernatants were transferred to 12 x 75 mm borosilicate glass 
tubes (Kimble Chase, Rockwood, TN, USA) and dried under a stream of nitrogen gas. 
The residue was resuspended in 20% methanol with 0.1% (v/v) formic acid (10% of 
original volume). To generate a standard curve, different concentrations of MMAE 
ranging from 0.017-3.33 ng/ml were mixed with 1.67 ng/ml D8-MMAE in lysates of 
untreated tumor cells and treated as above.   
Targeted liquid chromatography mass spectrometry (LC-MS/MS) analysis was 
performed using a Quantiva triple quadrupole mass spectrometer (Thermo Fisher 
Scientific) coupled to a binary pump HPLC (Ultimate 3000; Thermo Fisher Scientific). 
Chromatographic separation was achieved on a Hypersil Gold 5 µm, 50 mm x 3 mm 
column (Thermo Fisher Scientific) maintained at 30 °C using a solvent gradient method. 
Solvent A was H2O containing 0.1% (v/v) formic acid. Solvent B was acetonitrile 
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containing 0.1% (v/v) formic acid. The gradient method used was 0-1 min (20% B to 
60% B), 1-1.5 min (60% B to 95% B), 1.5-3 min (95% B), 3-4.1 min (95% B to 20% B), 
4.1-5 min (20% B) with a flow rate of 0.5 ml/min. The sheath, auxiliary, and sweeping 
gasses were set at 50, 15, and 1 arbitrary units, respectively. The spray voltage was set to 
3.5 kV and the vaporizer and capillary temperatures were maintained at 375 °C and 350 
°C, respectively. Transitions of 718.8 m/z -134.1 m/z and 727.6 m/z – 134.1 m/z were 
used for the quantitation of MMAE and D8-MMAE, respectively. Sample acquisition 
and data analysis were performed using TraceFinder (Thermo Fisher Scientific). 
 
3.4.13 Pharmacokinetic analyses 
Pharmacokinetic experiments were carried out in 7-10-week old female BALB/c 
SCID mice using protocols approved by the Texas A&M University IACUC. Lugol 
solution (Sigma-Aldrich) was added to drinking water 48-72 hours prior to starting the 
experiment, and maintained throughout the experiment. Mice were injected 
intravenously with 15 µg 125I-labeled ADC in 200 µl PBS with 0.1% (w/v) BSA. Whole 
body counts were measured using an Atom Lab 100 dose calibrator (Biodex, Shirley, 
NY, USA). Mice were retroorbitally bled with 10 µl capillary tubes (Drummond 
Scientific, Broomall, PA, USA) and radioactive counts measured by gamma counting 
(Perkin Elmer, Waltham, MA, USA). Radioactivity counts were normalized to the 




3.4.14 Therapy experiments 
Therapy experiments were carried out using protocols approved by the Texas 
A&M University IACUC. BALB/c SCID mice were purchased from Jackson 
Laboratories, bred and maintained in specific pathogen-free housing. 6-8-week old 
female mice were implanted with 3-5 x 106 MDA-MB-453 cells or 4-5 x 106 JIMT-1 
cells suspended in 100 µl 50% RPMI1640 media and 50% Matrigel (Corning, Corning, 
NY, USA) in the mammary fat pad. When the tumor size reached a volume of 50-100 
mm3, mice were randomized into groups and dosed intravenously with 2 mg/kg 
antibody, ADC, or vehicle twice with a three week interval (MDA-MB-453) or four 
times with one week intervals (JIMT-1). Tumor size was determined using the 
formula:  𝑡𝑢𝑚𝑜𝑟 𝑠𝑖𝑧𝑒 =
𝑡𝑢𝑚𝑜𝑟 𝑙𝑒𝑛𝑔𝑡ℎ × 𝑡𝑢𝑚𝑜𝑟 𝑤𝑖𝑑𝑡ℎ2
2
, where the tumor length and tumor 
width were measured with digital calipers every 3-4 days for the duration of the 
experiment. Mice with tumor volumes exceeding 2000 mm3 were euthanized. Alanine 
aminotransferase activity in serum samples from mice were analyzed using Alanine 
Aminotransferase Activity Assay Kits (Sigma-Aldrich) and the manufacturer’s protocol. 
 
3.4.15 Modeling analyses 
The X-ray crystallographic structure of the HER2-pertuzumab complex177 (PDB 
accession code: 1S78) was minimized using the molecular modeling software 
CHARMM v36213 in a CHARMM22 force field, and all missing residues and atoms 
were added. PROPKA v. 3.1214, 215 was used for empirical pKa prediction and 
protonation state determination for the minimized structure at pH 7.4 and 5.8, 
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respectively. The resulting structure at either pH value was minimized for 5,000 steps 
with explicit solvent molecules and then subjected to a 10 ns molecular dynamics (MD) 
simulation using the computer program NAMD2 v. 2.10216. MD protocols followed 
similar details as described previously217. Snapshots were retained at the 0th ns (the 
beginning) and every ns from the 6th to the 10th ns to represent a conformational 
ensemble of the HER2-pertuzumab complex at either pH. 
Structures of HER2 in complex with the SG mutant were modeled using iCFN218, 
an exact algorithm for multi-state protein design with substate ensembles, which was 
customized here for pH-dependence. First, the positive and negative substates were 
defined as conformational ensembles of the complex at pH 7.4 and 5.8, respectively. 
Substate energies were folding stabilities of the complex that include Coulomb 
electrostatics, van der Waals, calculated internal energies, and a nonpolar contribution to 
the hydration free energy based on solvent accessible surface area (SASA)218. A 
positive-substate stability cutoff was set at 10 kcal/mol and positive-versus-negative 
substate specificity was essentially not mandated with a cutoff of 1000 kcal/mol. 
Second, pertuzumab VH residues 55 and 57 were allowed to change to any amino acid, 
including histidines in 𝛿-, -, and doubly protonated states. Residues within 5 Å from the 
mutated amino acids were allowed to be flexible. In addition, His245 of HER2 was 
allowed to be in any of the 3 possible protonation states and Asp50 of pertuzumab VH 
was allowed to be deprotonated or singly protonated at either oxygen atom on the side 
chain. Top conformations of each sequence-protonation combination in each substate 
(backbone conformation here) generated from iCFN for either pH were geometrically 
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grouped into representatives and then screened by PROPKA for protonation states. 
Later, complex folding stabilities (G) and binding affinities (∆G) of the top sequence-
conformation ensembles retained for either pH were re-evaluated and re-ordered with a 
higher-resolution energy model where continuum electrostatics replaced Coulombic 
electrostatics218. Lastly, the representative conformation/protonation at either pH was 
chosen based on the best binding affinity (lowest ∆G) amongst those whose folding 
energies were within 1 kcal/mol of the most stable complex. 
Each calculated binding energy relative to WT, ∆∆G, was further decomposed 
into contributions of van der Waals (vdW), continuum electrostatics, SASA-dependent 
nonpolar solvation interactions, and internal energy. vdW and electrostatics were found 
to be the most important contributors to pH-dependent binding. The calculated vdW 
contribution was largely due to the modeled clashes between the bulkier pertuzumab 
His55 and a HER2 loop at pH 5.8 whereas the clashes could be largely ameliorated by 
the flexible HER2 loop. Therefore, long-range electrostatic binding affinity, being less 
sensitive to conformational details, was further analyzed as an origin of the pH-
dependent binding. Specifically, continuum electrostatics for binding were first 
decomposed into the contributions of the lost desolvation penalties and the gained 
solvent-screened intermolecular interactions. Desolvations were then decomposed into 
contributions of all residues and screened intermolecular electrostatic interactions into 
those of all residue pairs. To sum up screened intermolecular electrostatic interactions 
and avoid double counting for each residue, half of the pairwise interactions for each 
residue with all other residues were considered. Those residues with insignificant 
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contributions (desolvation plus the half of the summed pairwise interactions) to 
electrostatic binding specificity ∆∆∆G (∆∆∆G = ∆∆GpH 7.4 - ∆∆GpH 5.8) were not 
considered further. Since desolvation penalties dominated over screened electrostatic 
interactions in contributions to electrostatic binding specificity ∆∆∆G, the top 10 
remaining residues with the highest desolvation contributions were reported for ∆∆GpH 
7.4, ∆∆GpH 5.8, and ∆∆∆G, respectively.  
 
3.4.16 Statistical analyses 
Statistical significance was analyzed using two-tailed t-test, two-tailed Mann-
Whitney U test or one-way ANOVA with Tukey’s multiple comparison test as indicated 






The use of antibodies for the treatment of HER2-expressing cancers has had an 
enormous impact on the clinical use of this class of therapeutics. Initially, antibody 
therapies targeting HER2-expressing cancers were used exclusively to treat breast 
cancer, but have recently been found to have potential uses for the therapy of other 
malignancies such as gastric cancers219. Bladder, gallbladder, cervical, and uterine 
cancers, have also been shown to have subpopulations expressing HER2 and are being 
considered for HER2-targeted therapy220-222. However, despite the initial promise of 
trastuzumab, a high percentage of patients suffer from tumor relapse223. Consequently 
there is a need for improvement of these therapeutic approaches. 
One pathway through which HER2-expressing tumors escape following 
treatment with HER2-specific antibodies is through the intratumoral production of 
ligands for HER3 which drive the formation of HER2/HER3 heterodimers. These dimers 
are known to potently signal through the PI3K/Akt axis. In Section 2 of the thesis, this 
problem has been addressed by engineering a bsAb comprising the binding sites of a 
HER2-specific antibody, trastuzumab, and of a HER3-specific antibody. This bsAb has 
been used to target HER2 and HER3 simultaneously on tumor cells. In Section 3, we 
have investigated how to improve the delivery of a cytotoxic drug to HER2-expressing 
target cells by engineering the interactions of a HER2-specific antibody with HER2 to 
modulate the subcellular delivery properties of the corresponding ADC. Combined, 
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these studies demonstrate how antibody engineering can be used to produce therapeutic 
antibodies/ADCs with significantly improved efficacy.  
The study in Section 2 describes the effects of a bsAb that targets both HER2 and 
HER3 in the presence of HER3 ligand, heregulin. Co-treatment of HER2-expressing 
cells with the inhibitor of HER2 phosphorylation, lapatinib, and the HER2/HER3 bsAb 
results in potent inhibition of downstream PI3K/Akt signaling and inhibition of cell 
proliferation. By contrast, the combination of parent antibodies with lapatinib does not 
inhibit signaling in the presence of heregulin, leading to the activation of the PI3K/Akt 
pathway and ultimately cell survival and proliferation. In comparison with the parent 
monoclonal antibodies, the bsAb likely has a higher avidity for HER3 due to bridging 
effects of the trastuzumab portion of the bsAb binding to the excess of HER2, relative to 
HER3 level, on the cell surface (Figure 4-1), thereby locking the targeted receptors into 
dimers that cannot signal due to the presence of lapatinib. This approach represents a 
novel method for silencing a major signaling pathway that drives tumor cell 
proliferation. 
Despite the promise of ADCs as therapeutics, their efficacy in the clinic has been 
limited by dose-limiting toxicities that result in doses being used that can be insufficient 
to kill the tumor cells73. This problem is exacerbated when the target antigen expression 
is not high, such as in HER2-expressing cells that express intermediate levels of surface 
HER2 receptors. This issue is addressed in Section 3 by generating an ADC that is more 
effective in delivering its cytotoxic payload to lysosomes in target cells. In this study, an 
acid-switched ADC has been generated that comprises engineered pertuzumab variants 
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that bind to HER2 in a highly pH-dependent manner, with substantially lower affinity at 
endosomal (acidic) pH than at extracellular (near neutral) pH. Acid-switched ADCs 
result in increased payload delivery to late endosomal or lysosomal compartments and 
increased cytotoxicity. These effects are observed with tumor cells that express ~20 fold 
lower level of HER2 (HER2int). Significantly, treatment of tumor-bearing mice 
demonstrated that the acid-switched ADCs have higher therapeutic efficacy against 
HER2int tumor cells than an ADC comprising their parent wild type antibody and the 
clinically approved ADC, T-DM1. These results demonstrate the potential of using acid-
switched ADCs for increasing payload delivery to target cells and have broad 





Figure 4-1. HER2/HER3-specific bsAbs have higher avidity for HER3 due to the high 
expression of HER2 on the cell surface. BsAbs (left) bind tightly to HER2 on the cell 
surface which increases avidity for HER3. In comparison, parent HER3-specific 
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A1: Determination of drug-to-antibody ratios 
ADCs were analyzed using a hydrophobic interaction column (described in 
Section 3) and the following equation was used to determine the molar ratio of drug to 
antibody (DAR).  
 
𝐷0 ∗ 0 + 𝐷1 ∗ 1 + 𝐷2 ∗ 2




D0 = area under the curve (AUC) for the ADC population representing unconjugated 
antibody molecules. 
D1 = AUC for the ADC population with a DAR of 1. 
D2 = AUC for the ADC population with a DAR of 2.  
The ADCs used for the mass spectrometry data shown in Fig. 3-8b were calculated to 






A2: Generation of standard curves for mass spectrometry 
Representative standard curves used to determine the amount of MMAE in each 
tumor cell line are shown in Fig. A-1 and A-2 (see section 3.4.12 for tumor cell lysate 
preparation and processing). D8-MMAE was added to both standard and test samples at 
a concentration of 1.67 ng/ml (all samples were adjusted to 830,000 cells per ml in 
methanol) to account for losses during sample preparation. For the generation of 
standard curves, MMAE (0.017-3.33 ng/ml) was added to lysates of untreated tumor 
cells. During processing, the samples were concentrated 30-fold to result in standard 
concentrations ranging from 0.5-100 ng/ml. Mass spectrometry analyses of a defined 
volume of each standard sample resulted in an AUC value that was subsequently 
normalized relative to the AUC value for the internal D8-MMAE standard and plotted 
against the MMAE concentration. These plots were used to determine the concentrations 





Figure A-1. Representative standard curve for the determination of MMAE 





Figure A-2. Representative standard curve for the determination of MMAE 
concentrations in JIMT-1 cells. 
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